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 SUMMARY 
Awareness of cerebral white matter disorders has markedly increased since the 
introduction of magnetic resonance imaging (MRI). Although MRI is very sensitive in 
showing white matter signal abnormalities, the etiology of these changes often remains 
unknown. During the last decade, several new leukoencephalopathies have been 
delineated based on characteristic patterns of MRI changes for each of them. Recently, the 
genetic basis of some of these disorders has been elucidated. However, more than half of 
children with white matter abnormalities on brain MRI still have no specific diagnosis.  
 
The aim of this study was to classify patients with unknown cerebral white matter 
abnormalities and to identify new diseases among them. During the course of the study, 
three subgroups of patients were delineated and examined further.  
 
The study began by survey of 38 patients with undetermined leukoencephalopathy. 
Neurological, ophthalmological, and neurophysiological examinations were carried out to 
evaluate the spectrum of clinical manifestations. Biochemical and morphological 
investigations were performed to exclude known causes of leukoencephalopathies. Brain 
MRI findings were grouped into seven major categories according to the predominant 
location of the abnormalities. The largest subcategories were patients with myelination 
abnormalities (n=20) and patients with predominantly periventricular white matter 
abnormalities (n=12). 
 
Six patients shared a similar MRI pattern with hemispheric white matter abnormalities 
combined with changes in selective brain stem and spinal cord tracts. Magnetic resonance 
spectroscopy (MRS) showed consistently elevated lactate and decreased N-acetylaspartate 
(NAA) in the abnormal white matter. The patients presented at childhood or adolescence 
with sensory ataxia, tremor, distal spasticity, and signs of dorsal column dysfunction. The 
first description of this new phenotype – leukoencephalopathy with brain stem and spinal 
cord involvement and elevated white matter lactate (LBSL) – was published elsewhere in 
2003. A finding not described in the earlier patients was a mild axonal neuropathy, which 
develops in the later phase of the disease. The etiopathogenesis of this disease is unknown, 
but elevated white matter lactate in MRS suggests a mitochondrial disorder.  
 
Among the study patients, one child and his two first-degree relatives were found to have 
a small deletion of chromosome 18q. To better delineate the white matter changes related 
to 18q deletions, an additional 19 patients (age range 0.7-51 years) with previously 
diagnosed 18q deletions were investigated clinically and by MRI. The size of the deletion 
was determined using segregation analysis with microsatellite markers mapping to 18q. 
All patients with deletions between markers D18S469 (at 18q22.3) and D18S1141 (at 
18q23) had abnormal myelination in brain MRI. In infants, the myelination appeared 
severely delayed, and in older children and adults, the differentiation of the cerebral gray 
and white matter was poor on T2-weighted images, consistent with dysmyelination. 
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 The last part of the study comprised 13 patients (not included in the overview of unknown 
leukoencephalopathies) with strikingly similar MRI findings with leukoencephalopathy 
and progressive calcifications involving the thalami, cerebral and cerebellar white matter, 
brain stem, basal ganglia, and dentate nuclei. Five of the patients were studied 
prospectively and medical records of eight patients (of whom seven were deceased) with 
similar findings were reviewed. The patients showed a spectrum of findings, including 
progressive cerebral cysts, retinal telangiectasias and angiomas, intrauterine growth 
retardation, skeletal and hematologic abnormalities, and severe intestinal bleeding. 
Neurological symptoms were slowly progressive and included spasticity, ataxia, dystonia, 
seizures, and cognitive decline. The findings of these patients overlapped with features 
described previously in conjunction with two very rare disorders, namely “Coats plus” 
syndrome and “leukoencephalopathy with calcifications and cysts”, suggesting that these 
disorders are related. All six autopsied patients had similar neuropathological findings 
showing calcifying obliterative microangiopathy. The etiology of these changes is still 
unknown. The patients included two pairs of siblings, suggesting an autosomal recessive 
mode of inheritance.  
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 INTRODUCTION 
The diagnostics of cerebral white matter disorders was revolutionized by the advent of 
magnetic resonance imaging (MRI) in the late 1980s. While leukodystrophies were 
previously defined based on pathological findings, MRI has provided a powerful tool for 
investigating the cerebral white matter in living individuals.  
 
Within the last 15 years, knowledge of white matter disorders has grown rapidly. The 
previously known “classical” leukodystrophies have been demonstrated to show 
characteristic patterns of MRI abnormalities (138). New white matter diseases have been 
recognized, initially defined by their specific MRI features, and subsequently, gene defects 
underlying these diseases have been found. Examples of such novel disorders are the 
vanishing white matter (VWM) disease (52, 67, 129, 135), also called childhood ataxia 
with cerebral hypomyelination (CACH) (105), and megalencephalic leukoencephalopathy 
with subcortical cysts (MLC) (68, 137). The pathophysiological mechanisms underlying 
these disorders are under active investigation. 
 
Cerebral white matter is apparently involved in a large number of inherited metabolic 
diseases, chromosomal abnormalities, and acquired brain diseases. Despite this growing 
knowledge, when this study began, more than half of the children with white matter 
abnormalities on MRI remained without a specific diagnosis (62). This group of unknown 
leukoencephalopathies consists of rare and heterogeneous disorders, both progressive and 
nonprogressive (62). Without a diagnosis, predicting future outcome, assigning disease-
specific treatment and providing prenatal diagnostics are impossible. Also, in undefined 
leukoencephalopathy, extensive investigations are often needed, which are exhaustive for 
the children and family and expensive for the healthcare system. Thus, further studies to 
classify and characterize white matter disorders are warranted. Categorization of patients 
into subgroups, based on MRI findings, has been carried out to facilitate determination of 
new disorders and to enable comparison of the data across centers (62, 133). 
 
Many of the disorders with white matter involvement cannot be placed under the narrow 
concept of leukodystrophy, which implies inherited demyelinating disorders. The broader 
terms “white matter disorders” and “leukoencephalopathies” are defined as all conditions 
in which predominantly or exclusively white matter is affected, irrespective of the 
underlying histopathologic basis (125). Other important concepts used in this thesis are 1) 
“demyelination”, used when there is loss of myelin, 2) “hypomyelination”, which means 
that too little myelin is formed and this deficiency is permanent, 3) “dysmyelination”, used 
when the process of myelination is disturbed, leading to abnormal, patchy, or irregular 
myelination and 4) “delayed myelination”, used when the process of myelination is 
retarded but progressing.  
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 REVIEW OF THE LITERATURE 
1. White matter 
The central nervous system (CNS) comprises gray matter structures and an extensive array 
of connecting white matter tracts. The white matter is made up of myelinated axons, a 
large number of glial cells, and the blood vessels that nourish them. The glial cells include 
oligodendrocytes, which are myelin-forming cells, astrocytes, and microglial cells, which 
have a phagocytic function. On a dry weight basis, 40-50% of white matter is myelin (8). 
1.1 Myelin sheath 
Myelin is a multilayered substance that surrounds the axons. It is present both in the 
central and in the peripheral nervous system (PNS), but the myelin-forming cells and 
composition of myelin differ between these two systems.  In the CNS, myelin is formed 
by oligodendrocytes. The myelin sheath is an extended, modified oligodendrocyte plasma 
membrane surrouding a portion of an axon in a spiral fashion (Figure 1). Each 
oligodendrocyte may wrap up to 40 axons, and on the same axon, adjacent myelin 
segments belong to different oligodendrocytes. Small unmyelinated regions of axons 
between two segments of myelin, the nodes of Ranvier, contain a cluster of voltage-gated 
sodium channels. When the axon membrane is excitated, the electrical impulse does not 
flow through the high-resistance myelin sheath, but jumps from node to node. The low 
capacitance of the sheath allows depolarization of the remaining membrane between the 
nodes. This saltatory conduction of nerve impulses allows the fast nerve conduction that is 
crucial for functional integration of the CNS [reviewed in (8, 125)]. 
 
Figure  1. The relationship between an oligodendrocyte and myelinated nerve fibers in the CNS. 
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 1.2 Composition of the myelin membrane 
The myelin membrane is a lipid bilayer interrupted by proteins (Figure 2). Compared with 
other membranes, the composition of myelin is unique, with low water content (40%) and 
a very high lipid content. On a dry weight basis, myelin contains 70% lipids and 30% 
proteins (8).  
 
 
Figure  2. Composition of myelin. The myelin membrane is composed of repeated layers with 
protein-lipid-protein-lipid-protein structure. Glycolipids and cholesterol are located 
at the extracellular faces and phospholipids at the cytoplasmic (intracellular) faces of 
the lipid bilayer. The presence and relative amounts of myelin proteins differ between 
the CNS and PNS. In  compact CNS myelin, MBP and PLP are the major proteins. 
While P0 and PMP22 are found only in the PNS, MOG is specific for CNS myelin. 
The closely apposed external faces of the myelin membrane form the double 
intraperiod lines.The fused internal faces of the membrane form the major dense lines 
(see also Fig.1). Circles represent IgG-like domains, and triangles N-linked 
oligosaccharides of the proteins. P0, myelin protein zero; PMP22, peripheral myelin 
protein 22; Cx32, connexin 32. Adapted from (8, 98). 
Most myelin proteins are unique to myelin. Each protein is localized at a specific site in 
the myelin membrane, reflecting its function. The two major proteins of CNS myelin are 
proteolipid protein (PLP) and myelin basic protein (MBP), accounting for 50% and 30% 
of the total protein, respectively. Both are found in different isoforms, which are produced 
by alternative splicing of their genes. MBP is necessary for myelin compaction, adhering 
the cytoplasmic leaflets of the myelin membrane, while PLP (and its isoform DM20) 
stabilizes the intraperiod line of the membrane (21). In addition, myelin contains several 
minor proteins, e.g. glycoproteins MAG (myelin-associated glycoprotein) and MOG 
(myelin-oligodendrocyte protein). MAG is localized in the periaxonal myelin membrane 
and participates in signaling between axons and glia. This axon-glia interaction is 
suggested to be important in, for example, promoting myelin formation (98). MOG is 
localized on the outside surface of the myelin sheaths and oligodendrocytes. It is proposed 
to transmit signals from the extracellular environment and to be an important target in 
autoimmune demyelinating diseases (98). CNP (2’3’-cyclic nucleotide 3’-
13
 phosphodiesterase) is only found in noncompact parts of myelin, e.g. in paranodal loops. 
CNP is not important for myelin assembly, but is essential for axonal survival (65). 
 
The myelin lipids cholesterol, phospholipids, and glycolipids are not specific to myelin, 
but are also found in other cellular membranes. However, glycolipids, in particular 
galactocylceramides and sulfatides, and ethanolamine plasmalogen are highly enriched in 
myelin. Gangliosides are minor lipids of myelin, more abundantly localized in neuronal 
membranes. A special feature of myelin lipids is a high amount of monounsaturated long-
chain fatty acids, resulting in the membrane being tightly packed and stabile (8).  
1.3 Astrocytes 
Astrocytes are glial cells found throughout the CNS. They interact with each other and 
with other glial cells by gap junctions and have multiple functions (63). In the white 
matter, astrocytes have a role in controlling the onset of myelination by inducing the 
adhesion of oligodendrocyte processes to axons. They also stimulate myelin formation and 
remyelination by secreting growth factors (8, 144). Triggered by cell damage, astrocytes 
proliferate and accumulate glycogen and filaments, a state known as gliosis.  
1.4 Process of myelination in the central nervous system 
Myelination starts during the fifth month of fetal life at the spinal cord. It proceeds 
rostrocaudally (from head to tail) in the spinal cord and from the spinomedullary junction 
to the forebrain in the cerebrum. CNS tracts begin myelinating when they become 
functional (125). The peak of myelin formation occurs during the first postnatal year, but 
myelination may progress slowly until 20 years of age in some cortical fibers, especially 
in associative areas (8). Myelination is a strictly regulated process and requires 
coordinated expression of genes responsible for synthesis of myelin components (34). An 
active field of research deals with the complex cellular mechanisms needed to determine 
how the oligodendrocytes migrate towards the axons and recognize them, how the 
interaction of glia and axons is initiated, how the spiraling of myelin occurs around an 
axon, and how the nodes of Ranvier are formed (27, 110). While active myelination is a 
vulnerable process, mature myelin is quite stable and resistant to alterations. 
1.5 Different forms of myelin disturbance 
Various types of underlying pathology are found in myelin disorders [reviewed in (131)], 
and most disorders include a combination of different pathologies. 
 
The complex process of myelin assembly may be disturbed by different genetic and 
acquired factors. The best-known example of a severe hypomyelinating disorder is 
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 Pelizaeus-Merzbacher disease (PMD), which is caused by defects in the PLP gene (56, 
109). A disturbance of myelination may also lead to patchy or irregular myelination. This 
kind of dysmyelination is seen in, for example, certain disorders of amino acid metabolism 
such as serine synthesis defects (30). Also, if a predominantly neuronal degenerative 
disorder has an early infantile onset, the process of active myelination may be disrupted, 
as in INCL (infantile neuronal ceroid lipofuscinosis) (141) and GM1 and GM2 
gangliosidoses (23, 48). 
 
Demyelination of the previously normal myelin sheath is seen in, for example, acquired 
inflammatory white matter diseases such as multiple sclerosis (MS) (55). Demyelination is 
also a predominant pathology in “classical” leukodystrophies, including metachromatic 
leukodystrophy (MLD) and X-linked adrenoleukodystrophy (X-ALD) (43, 82). In these 
disorders, the composition and degradation of myelin lipids are altered, leading to 
structurally unstable myelin and eventually to demyelination.  
 
The intramyelinic vacuole formation may result in myelin splitting, with or without 
concomitant demyelination. This occurs in MLC (136), in organic acidurias, such as 
Canavan disease (60), and in some mitochondriopathies (88). Moreover, intoxications, e.g. 
inhalation of heroin vapor (61), may cause myelin splitting.  
 
Damage to oligodendrocytes leads to disturbance of both the formation and maintenance 
of myelin. This is seen, for instance, in Krabbe disease, where accumulation of the toxic 
substance psychosine causes rapid and almost complete oligodendrocyte cell death (115). 
1.6 Interaction between glial cells and axons after myelination 
The myelin sheath and axon are mutually dependent on each other. If the axon is 
destroyed, the myelin sheath distal to the lesion is lost, a process called Wallerian 
degeneration. Recently, the long-term maintenance of the normal structure and function of 
the axon has been shown to be dependent on normal myelin function (46, 110). Evidence 
for axonal damage has been found in humans and animals with myelin protein deficiencies 
and in the acquired demyelinating disease MS. This axonal damage also occurs in areas 
without overt signs of demyelination or damaged oligodendrocytes (15, 32, 39, 47). 
Moreover, mice lacking a minor myelin protein CNP have no apparent myelin 
abnormality, but they gradually develop axonal swelling and degeneration (65). Thus, 
probably the disruption of the axon-glia interaction rather than demyelination is the cause 
of this axonal degeneration (39). 
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 2. Magnetic resonance in investigating white matter disorders 
The most important clinical tools for investigating white matter disorders in living patients 
are MRI, which shows macroscopic structural changes, and MRS, which reveals 
biochemical changes in the brain. 
2.1 Magnetic resonance imaging (MRI)  
MRI is very sensitive in showing signal abnormalities in the white matter. Apart from 
myelin disturbances (hypomyelination, dysmyelination, and demyelination), damage to 
other components of the white matter may contribute to the observed signal abnormality. 
These include edema, seen for instance in conjunction with increased vascular 
permeability (116), and gliosis, which occurs when astrocytes react to diverse forms of 
injury (131). Axonal damage may also contribute to white matter signal abnormalities, as 
is seen in giant axonal neuropathy (19). 
 
T1-weighted images are used to assess the anatomic structures. During the early phases of 
myelination, small amounts of myelin are better visualized on T1-weighted images. On 
these images, normally myelinated white matter appears bright and cerebrospinal fluid 
(CSF) is black. Pathological white matter gives a decreased signal and appears dark on 
T1-weighted images.  
 
T2-weighted images are superior in showing the pathological processes of white matter. 
For subjects aged 9-10 months or beyond, T2-weighted images are more useful in 
evaluating the stage of myelination. Normal myelinated white matter appears dark and 
CSF is bright on these images. Pathology in the white matter leads to an abnormally high 
signal on T2-weighted images. 
 
FLAIR (Fluid attenuated inversion recovery) is a T2-weighted sequence, where the signal 
of the free fluid, e.g. CSF, is nullified. In these images, the CSF is black and myelinated 
white matter is dark. If white matter is pathologic, it appears hyperintense and especially 
periventricular lesions are easily distinguished. The cystic nature of the lesions is also 
revealed by FLAIR images.  
 
As the white matter myelinates, it changes from hypointense (dark) to hyperintense 
(bright) relative to gray matter on T1-weighted images and from hyperintense to 
hypointense relative to gray matter on T2-weighted images. These changes in signal 
intensity are caused by increasing brain lipid concentration and decreasing water content 
(6). The myelin signal appears earlier on T1-weighted images. In a newborn, myelin is 
seen in the posterior limbs of the internal capsules and in the dorsal brainstem (Table 1, 
Figure 3). During the first year of life, progressive myelination is seen, with sensorimotor 
and visual pathways maturating first and subcortical association areas maturing last 
(Figure 3)(5, 7). By the age of 24 months, myelination appears essentially mature in MRI 
(6).  
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Figure  3. Progress of myelination on T1-weighted (upper row) and T2-weighted (lower row) 
MRIs. In a newborn (a) and (d), the myelinated white matter is seen in the posterior 
limbs of the internal capsule. It appears hyperintense on T1-weighted images and 
hypointense on T2-weighted images.  By the age of 8 months (b) and (e), the deep 
white matter is hyperintense on T1-weighted images, but the subcortical areas are 
still mostly unmyelinated. Hypointensity on T2-weighted images lags behind. By 24 
months (c) and (f), the brain is fully myelinated on both  T1- and T2-weighted images.  
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Table  1. Progress of myelination visible on MRI. Modified from (5, 7). 
Region T1-weighted images T2-weighted images 
 
 
Dorsal brainstem 
 
26-28 gw 
 
27-30 gw 
Middle cerebellar peduncle Birth Birth-2 mo 
Cerebellar white matter Birth-4 mo 3-5 mo 
Posterior limb of the internal 
capsule 
  
     anterior portion First month 4-7 mo 
     posterior portion Birth Birth- 2 mo 
Anterior limb of the internal 
capsule 
2-3 mo 7-11 mo 
Genu corpus callosum 4-6 mo 5-8 mo 
Splenium corpus callosum 3-4 mo 4-6 mo 
Occipital white matter 
     central 
     subcortical 
 
3-5 mo 
4-7 mo 
 
9-14 mo 
11-15 mo 
Frontal white matter 
     central  
     subcortical 
 
3-6 mo 
7-18 mo 
 
11-18 mo 
14-30 mo 
Centrum semiovale 2-4 mo 7-11 mo 
 
gw, gestational weeks; mo, months 
2.2 Magnetic resonance spectroscopy (MRS) 
 MRS provides a noninvasive method for identifying and quantifying brain metabolites. 
Several nuclei can be used, but proton MRS (1H-MRS) is the most widely applied method 
in clinical settings. MRS, like MRI, is based on nuclear magnetic resonance. The nuclei, in 
1H-MRS protons, resonate at a slightly different frequency in different chemical 
environments. From the measured frequency spectrum, one can deduce the chemical 
composition of the target tissue. Because the concentrations of the investigated 
metabolites are much lower than the concentration of the water in the tissue, the water 
signal must be suppressed in 1H-MRS. In single-voxel MRS, only one region of interest is 
measured. In magnetic resonance spectroscopic imaging (MRSI), multiple spectra 
covering a larger volume of brain are obtained simultaneously. 
 
The major peaks in the human 1H-MR spectrum are N-acetylaspartate (NAA), choline-
containing compounds (Cho), and total creatine (Cr), including creatine and 
phosphocreatine (Figure 4). Lactate (Lac) is normally not detected, but it is visualized if 
elevated. NAA is an amino acid found only in the CNS, and it is considered a specific 
neuroaxonal marker (12). Cho is elevated when membrane turnover is enhanced, both in 
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 anabolic (myelination) (139) and in catabolic (demyelination and tumor growth) (11, 50) 
conditions. The concentration of Cr is high in glia, and thus, increased Cr is seen in 
conditions of gliosis (125). Lac increases in anaerobic glycolysis, as in hypoxia or in 
disorders of mitochondrial energy production. It may also be produced by metabolism of 
macrophages (73). Thus, elevated Lac is seen in conditions with increased numbers of 
macrophages, such as in inflammation occurring with active demyelination or in tissue 
necrosis (11). The major metabolites are visualized in spectra at long echo times (135-288 
ms). More peaks are identified using short echo time (20-30 ms), e.g. myo-inositol (MIns). 
MIns is believed to be an astrocytic marker, and it is increased in conditions of gliosis 
(102). It is also an osmoregulator (107). However, with short echo times, quantification of 
peaks is more difficult than with long echo times. 
 
Figure  4. In an 1H-MR spectrum, each peak represents a proton in a particular compound. The 
area under each peak is proportional to the number of protons producing that peak. 
The chemical shifts (differences in resonance frequencies) are expressed in relative 
units (parts per million, ppm). The major peaks represent N-acetylaspartate (NAA), 
choline- containing compounds (Cho), and creatine (Cr). 
The MR spectrum changes during brain maturation. The NAA peak increases most rapidly 
during the first years of life, and this increase is suggested to reflect the formation of 
dendritic arborization and synaptic connections (96, 139). The prominent Cho peak in 
young infants probably reflects high membrane synthesis and turnover related to myelin 
formation. In white matter, Cho concentrations in older children (5-18 years) are about 
15% below the levels in infants and young children (0-5 years) but the concentration of Cr 
remains stable after 1 year of age (96). 
 
A shortcoming of MRS is that it is rather insensitive. The metabolites must have a 
concentration of at least millimolar range, and they also need to be small and mobile to be 
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 visible in MRS. Macromolecules, such as proteins and membrane components, are 
“invisible” in MRS . Thus, normal myelin is mostly inaccessible to MRS. However, 
breakdown products of myelin membranes, like choline, may be detected. 
3. Hereditary diseases with cerebral white matter involvement 
Cerebral white matter abnormalities are found in many inherited diseases, examples of 
which are given in Table 2. Among “classical” leukodystrophies, MLD, Krabbe disease, 
and X-ALD are lysosomal and peroxisomal diseases in which progressive demyelination 
occurs in both the CNS and the PNS (42, 82, 115). Alexander disease is a primary 
astrocytic disorder caused by dominant mutations of the glial fibrillary acidic protein 
(GFAP) gene (16). Canavan disease is an organic acid disorder with spongiform 
leukoencephalopathy (76), and Pelizaeus-Merzbacher disease is an X-linked 
hypomyelinating disorder (109), caused by defects in the gene coding for PLP, a major 
protein of the myelin membrane (56). In recent years, it has become clear that severe 
leukoencephalopathy may be the predominant MRI finding also in mitochondrial 
disorders (31, 81, 123).  
 
Some of the new phenotypes of childhood-onset leukoencephalopathies, recently 
recognized by their specific MRI patterns, are presented briefly here, as well as 18q- 
syndrome.  
3.1 Leukoencephalopathy with vanishing white matter (VWM) 
In this peculiar disease, the cerebral white matter slowly disappears. However, the brain 
does not collapse because the vanished white matter is replaced by fluid. FLAIR images 
are needed to show the rarefaction and cystic degeneration of the white matter (135).  
 
Clinically, this disorder is characterized by progressive ataxia, followed by spasticity. 
Mental decline is relatively mild compared with severe motor handicap. Optic atrophy and 
seizures may occur as well (52, 135). Characteristic are episodes of rapid deterioration 
which may be provoked by mild head trauma, febrile infections, or stress. These episodes 
can lead to coma and death, and if the patient survives, the recovery is usually incomplete 
(135, 143). The most common variant of VWM has its onset in childhood, usually 
between the ages of 2 and 6 years. In the severe infantile-onset variant, death ensues 
before 2 years of age. Infantile cases may show multisystem involvement, with growth 
retardation, cataracts, hepatosplenomegaly, and pancreatic abnormalities (127). The adult-
onset variant of VWM may manifest with seizures, cognitive and behavioral 
abnormalities, or motor deterioration (10, 36). In females, primary or secondary ovarian 
dysfunction may occur (37, 104).  
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 Table  2. Examples of hereditary disorders with cerebral white matter abnormalities (3, 93, 
122, 125). 
 
Lysosomal disorders Mitochondrial disorders Neurocutaneous disorders 
Metachromatic leuko- Leber’s hereditary optic  Tuberosis sclerosis 
dystrophy neuropathy Hypomelanosis of Ito 
Krabbe disease Mitochondrial encephalo- Neurofibromatosis type I 
GM1 and GM2 myopathy with lactic 
gangliosidosis acidosis and stroke- Other 
Multiple sulfatase like episodes  Alexander disease 
deficiency Leigh syndrome Vanishing white matter disease 
Free sialic acid storage Mitochondrial neurogastro- Megalencephalic leukoencephalo- 
disorders intestinal encephalomyopathy pathy with subcortical cysts 
Aspartylglucosaminuria Kearns-Sayre syndrome  Hypomyelination with atrophy of 
Neuronal ceroid Isolated deficiencies of  the basal ganglia and cerebellum 
lipofuscinoses respiratory chain complexes Leukoencephalopathy with 
Fabry disease Pyruvate dehydrogenase involvement of brain stem 
Fucosidosis complex deficiency and spinal cord and high lactate 
Mucopolysaccharidoses Pyruvate carboxylase Aicardi-Goutières syndrome 
Adult polyglycosan body deficiency Leukoencephalopathy with 
disease Multiple carboxylase calcifications and cysts 
 deficiency Giant axonal neuropathy 
Peroxisomal disorders  Cerebrotendinous xanthomatosis 
Peroxisome biogenesis Defects in genes encoding Lowe syndrome  
defects myelin proteins  Sjögren-Larsson syndrome 
X-linked adrenoleuko- Pelizaeus-Merzbacher disease  Wilson disease 
dystrophy and  Sulfite oxidase deficiency and 
adrenomyeloneuropathy Defects of nuclear molybdenum cofactor deficiency 
Bifunctional protein DNA repair Galactosemia 
deficiency Cockayne syndrome Hereditary diffuse leukoencephalopathy 
Rhizomelic chondro- Trichothiodystrophy with neuroaxonal spheroids 
dysplasia punctata  Dentatorubropallidoluysian 
Acyl-CoA oxidase Muscular dystrophies atrophy 
deficiency Congenital muscular Cerebral autosomal dominant 
 dystrophies arteriopathy with subcortical 
Disorders of amino  Myotonic dystrophy  infarcts and leukoencephalopathy 
acid and organic acid  Cerebral autosomal recessive 
metabolism Macro-/microdeletion arteriopathy with 
L-2 and D-2 hydroxy-  syndromes subcortical infarcts and  
glutaric aciduria  18q- deletions leukoencephalopathy 
Canavan disease 11q- deletions Nasu-Hakola disease 
Methylmalonic aciduria 6p- deletions Pigmentary  orthochromatic 
HMG coenzyme A lyase Angelman syndrome leukodystrophy 
deficiency  Adult autosomal dominant 
Maple syrup urine disease Defects in connexin genes leukoencephalopathies 
Nonketotic hyper- Oculodentodigital dysplasia  
glycinemia Hypomyelination with   
Hyperhomocysteinemias mutations in a gene  
Phenylketonuria encoding GJA12 
Serine synthesis defects  
Glutaric aciduria type I  
Propionic acidemia  
Urea cycle defects  
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 VWM is inherited in an autosomal recessive mode and is related to gene defects in 
eukaryotic translation initiation factor 2B (eIF2B) (67). eIF2B is a protein complex with 
five subunits encoded by five different genes (EIF2B1-EIF2B5). Missense mutations of 
any of these genes may cause VWM (129). eIF2B is required for protein synthesis 
initiation and regulation. Under stress conditions, as in fever, protein synthesis is in 
healthy individuals downregulated. This regulation is postulated to be deteriorated in 
VWM, leading to misfolding and denaturation of proteins (127). However, the association 
between eIF2B mutations and pathophysiological mechanisms of VWM remains poorly 
understood. Also unknown is why the cerebral white matter is predominantly affected 
since eIF2B is expressed in all cells of the body (127).  
3.2 Megalencephalic leukoencephalopathy with subcortical cysts (MLC) 
This autosomal recessive disorder is characterized by infantile onset macrocephaly and 
extensive cerebral white matter changes, with swelling and subcortical cysts found mainly 
in temporal regions (137). Considering the severe white matter changes, the initial 
manifestations are surprisingly mild, with normal or mildly delayed motor development. 
After an interval of several years, a slowly progressive ataxia and spasticity occur. Most 
children are wheelchair-dependent at the end of the first decade or in the second decade of 
life (9, 111, 121, 137). Epilepsy is common and seizure episodes may be triggered by 
minor head trauma (111). Most patients have normal or low-normal cognitive capacity. In 
some cases, mild cognitive deterioration occurs (111). 
 
Little is known about the pathogenesis of MLC. Brain biopsy of one patient showed the 
presence of innumerable vacuoles and intense astrogliosis in the cerebral white matter. 
Electron microscopy revealed splitting of the outer lamellae of the myelin membrane 
(136). One gene related to MLC was identified in 2001 and named MLC1 (68). MLC1 
encodes a membrane protein of unknown function. In the brain, MLC1 is expressed 
especially in astrocytic endfeets, but not in oligodendrocytes (117).  This expression is 
concentrated at the blood-brain barrier and at the brain–CSF barrier, suggesting that 
MLC1 participates in the transport of ions or other substances (14, 117). Thus, astrocytic 
dysfunction might play a primary role in MLC. Mutations of MLC1 have been found in 
only 60-70% of patients with typical MRI findings (125) implying that more than one 
gene is involved. This disorder is more prevalent in an Indian Agarwal community (111) 
and in Turkey (121) than elsewhere. 
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 a b 
Figure  5. Brain MRI of a patient with MLC. The cerebral white matter appears diffusely 
hyperintense and swollen on a T2-weighted image (a). A T1-weighted image (b) 
shows the typical subcortical cysts at the temporal lobes. 
3.3 Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) 
The diagnostic MRI pattern of this disorder consists of a combination of severe 
hypomyelination and progressive atrophy of the putamen, caudate nucleus, and 
cerebellum. Eight patients have been described to date (77, 130). 
 
The majority of these patients had delayed motor development and onset of motor 
deterioration at the age of 2-6 years. They showed spasticity, ataxia, dysarthria, and 
prominent extrapyramidal movement abnormalities, including dystonia, choreoathetosis, 
and rigidity. All patients had learning difficulties or mental retardation, but no marked 
cognitive decline. In the severe form of the disease, the onset was within the first months 
of life, manifesting as poor visual contact, hypotonia, and absent motor development (77, 
130). No underlying genetic defect has been identified. 
3.4. Leukoencephalopathy with brain stem and spinal cord involvement and elevated 
white matter lactate (LBSL) 
The first description of this new leukoencephalopathy published in 2003 (128) included 
eight patients with slowly progressive pyramidal, cerebellar, and often dorsal column 
dysfunction. Brain MRI was characterized by inhomogeneous signal abnormalities in 
periventricular and deep white matter in combination with selective involvement of certain 
brain stem and spinal cord tracts. The pyramidal tracts were shown to be affected over 
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 their entire length. The sensory tracts, including dorsal columns, medial lemniscus, and 
corona radiata were also involved over their entire length. In addition, the tracts of the 
trigeminal nerve and cerebellar connections were selectively involved. MRS showed a 
significant decrease in NAA, an increase in myoinositol, normal or mildly elevated Cho, 
and elevated Lac within the white matter of all patients. 
 
The pathophysiology of this disease is unknown, but based on MRS findings and 
involvement of the entire sensory and pyramidal tracts, the disease process has been 
proposed to primarily involve white matter axons (128) . 
3.5 18q- syndrome 
MBP is a major protein of the CNS myelin membrane. Mutations of the MBP gene have 
not been found in humans. However, the MBP gene region (18q23) is commonly deleted 
in patients with partial deletions of the long arm of chromosome 18. The phenotype in 
18q- syndrome is variable, but neurologic features, including tremor, dyscoordination, 
oculomotor problems, and mental retardation, are commonly reported, as are short stature, 
foot deformities, midface hypoplasia, hypotonia, hearing impairment, atretic or stenotic 
external auditory canals, and genitourinary malformations (41, 72, 78, 113, 147).  
 
Patients with 18q- syndrome are reported to have diverse cerebral white matter 
abnormalities, including delayed or incomplete myelination, periventricular and focal deep 
white matter lesions and poor differentiation of gray and white matter (78, 90, 114, 146). 
A previous study with 16 patients (72) found diffuse or focal white matter abnormalities in 
60% of 18q- syndrome patients, but was unable to reveal a constant pattern of findings 
Another study, by contrast, showed a more consistent pattern, with incomplete 
myelination as a typical finding (41). In the latter study, a single patient with normal brain 
MRI had an interstitial deletion of 18q which spared the region for the MBP gene. Thus, 
haploinsufficiency of the MBP was suggested as the cause of the abnormal myelination 
(41).  
 
The specificity of these MRI findings has been questioned (38) because white matter 
abnormalities are found in other chromosomal abnormalities as well, e.g. in partial 
deletions of chromosomes 11, 22, and 6 and in sex chromosomal disorders (40, 89, 145). 
3.6 Leukoencephalopathy with calcifications and cysts 
A rare disorder with leukoencephalopathy, extensive brain calcifications, and progressive 
intracranial cysts has been reported in six patients previously. Findings in brain biopsies 
have suggested that this is a microangiopathic disorder (64, 83). Similar white matter 
changes and calcifications, but no cyst formation, have been reported in several patients 
with bilateral retinal telangiectasias and exudations (“Coats’ disease”) (29, 45, 100, 103, 
119). Some of these patients have also had other manifestations, including intrauterine 
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 growth retardation, sparse hair, dysplastic nails, skeletal abnormalities, and pancytopenia, 
and have often been reported as cases of a “new” syndrome. Based on one patient with 
overlapping findings (both cysts and Coats’ disease and calcifications and 
leukoencephalopathy), these disorders were proposed to be related (83). 
4. Acquired disorders with cerebral white matter involvement 
A thorough discussion of acquired white matter disorders (Table 3) is beyond the scope of 
this thesis. However, congenital cytomegalovirus (CMV) infection may cause white 
matter abnormalities, which are often confused with hereditary leukoencephalopathies, 
and this disorder is therefore discussed here. 
4.1 Congenital cytomegalovirus infection 
Cytomegalovirus is the most common cause of congenital viral infections throughout the 
world, occurring in about 1% of all live births (1). Approximately 10% of infected infants 
are symptomatic at birth. Common manifestations are petechiae, hepatosplenomegaly, 
jaundice, microcephaly, and chorioretinitis. However, 90% of infected infants are 
asymptomatic at birth, with 5-17% of these infants developing long-term sequelae (99). 
The long-term problems are nonprogressive and include sensorineural hearing deficit, 
learning problems, epilepsy, mental retardation, and motor deficits ranging from 
coordination problems to severe motor handicap. 
 
To diagnose congenital CMV infection, the antibody tests should be performed within the 
first 3 weeks of life. Thus, in patients who were asymptomatic at birth, the diagnosis 
usually cannot be confirmed retrospectively. However, in most Western countries, the 
blood spots of neonates are collected on filter paper (Guthrie cards) and used for screening 
tests for treatable infantile diseases. Using stored Guthrie cards, CMV DNA can be tested 
by polymerase chain reaction (PCR). The typical pattern of white matter abnormalities 
caused by congenital CMV infections was recently elucidated in an elegant study, where 
congenital CMV infection was retrospectively confirmed by PCR (126). In milder cases, 
the suggestive MRI pattern was found to consist of multifocal lobar white matter lesions 
that were most pronounced in the parietal area and relatively spared the immediately 
periventricular and subcortical white matter (Figure 6). In more severe cases, there may be 
concomitant gyration abnormalities (polymicrogyria), and the white matter abnormalities 
may also be diffuse (Figure 7). In particular, abnormalities of the anterior temporal lobe, 
including swollen white matter and cysts, are suggestive of congenital CMV infection 
(126).  
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  a b 
Figure  6. T2-weighted images of a 2-year-old girl show mild, patchy, multifocal white matter 
abnormalities in the lobar white matter (a) and in the anterior temporal lobe (b), a 
typical pattern for congenital CMV infection. 
 
 a b 
Figure  7. T2-weighted images of an 11-year-old girl with static encephalopathy and 
sensorineural hearing impairment show severe changes typical of congenital CMV 
infection. The gyration is abnormal (a) and diffuse white matter signal abnormalities 
are prominent, especially in the temporal lobes (b). 
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Table  3. Acquired disorders with cerebral white matter abnormalities in the pediatric age 
group. 
 
Noninfectious inflammatory Toxic-metabolic disorders Hypoxic-ischemic disorders
disorders  Endogenous and exogenous  Post-hypoxic-ischemic 
Multiple sclerosis and variants toxins leukoencephalopathy 
Acute disseminated  Central pontine myelinolysis 
encephalomyelitis  Salt intoxication  Traumatic disorders 
Systemic lupus erythematosus Vitamin B12 and folate Diffuse axonal injury 
Sarcoidosis deficiency  
Vasculitis Malnutrition Other 
 Posterior reversible Radiation damage
Infectious inflammatory  leukoencephalopathy 
disorders  
Subacute HIV encephalitis    
Progressive multifocal   
leukoencephalopathy    
 
 
Neuroborreliosis    
Subacute sclerosing panencephalitis    
Congenital cytomegalovirus infection   
Brucellosis    
Whipple disease 
Other infections 
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 AIMS OF THE STUDY 
The initial aim of this work was to classify patients with unknown cerebral white matter 
abnormalities and to identify new diseases among them. During the course of the study, 
three subgroups were delineated and examined further. The following subgoals were set: 
 
a) to characterize clinical and MRI findings in patients with a novel leukoencephalopathy 
with brain stem and spinal cord involvement and high white matter lactate in MRS 
(LBSL) (Study I) 
 
b) to determine whether any specific patterns of white matter abnormalities are present in 
patients with 18q deletions and to correlate these findings with molecularly defined size of 
the deletion (Studies II and III) 
 
c) to describe clinical and radiological findings in patients with leukoencephalopathy, 
cerebral calcifications, cysts, and retinal vascular abnormalities (Study IV) 
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 PATIENTS AND METHODS 
1. Patients 
1.1 Overview of leukoencephalopathies of unknown etiology (unpublished data) 
Patients with white matter abnormalities, detected by MRI, were found through the 
following sources: 1) patients evaluated by MRI at the Department of Child Neurology, 
Hospital for Children and Adolescents, University of Helsinki, during 2000-2005, 2) 
patients sent for consultation from other hospitals in Finland or Estonia (n=3) due to white 
matter abnormalities, and 3) patients traced by reviewing the notes of neuroradiological 
meetings, held in years 1990-1999 in the above mentioned hospital. 
 
Inclusion criteria were: 
1. Sufficient medical records and available MRIs. 
2. MRIs showing siqnificant white matter signal intensity abnormalities, including 
severely delayed myelination (i.e. myelination age of 6-8 months or less at patient’s age of 
over 1 year).  
3. In cases with combined pathology of white and gray matter, the white matter 
abnormality was predominant. 
 
Excluded were cases with  
1. A known diagnosis. 
2. Only minor white matter involvement (slight delay in myelination or only a few isolated 
T2 hyperintense spots). 
3. Predominantly gray matter involvement. These included cases where marked cerebral 
atrophy  was accompanied by solely white matter volume loss, but not signal abnormality, 
and cases with severe gyration or migration abnormalities. 
 
Forty-six patients fulfilled the above-mentioned criteria. Of these patients, two were 
deceased and six were not accessible or were unwilling to participate in further studies. 
The remaining 38 patients, including five sib-pairs, entered the study. 
1.2 Leukoencephalopathy with brainstem and spinal cord involvement and elevated white 
matter lactate (Study I, unpublished data) 
Among patients with undetermined leukoencephalopathy, six patients, including two 
siblings, with similar clinical and  MRI features were identified. Five of the patients are 
described in Study I, after which one additional patient entered the study. 
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 1.3 18q deletions (Studies II and III) 
Among patients with undetermined leukoencephalopathy, one patient and his two first-
degree relatives were found to have a partial deletion of the long arm of chromosome 18. 
An additional 19 patients with 18q deletions, diagnosed previously at our clinic or 
identified through cytogenetic laboratories, participated. The age range of patients (13 
males, 9 females) was 0.7- 51 years, and their 18q deletions were caused by terminal de 
novo deletions (eight patients), inherited deletions (two families each with an affected 
parent and two affected children) or unbalanced translocations (eight patients from three 
families). All patients participated in the MRI study (Studies II and III) but patients with 
translocations were excluded from phenotype-genotype correlation analyses. 
1.4 Leukoencephalopathy with cerebral calcifications (Study IV) 
Thirteen patients with leukoencephalopathy combined with extensive cerebral 
calcifications were not included in the overview of unknown leukoencephalopathies, but 
were identified through the following sources: 1) they were former or current patients of 
the Hospital for Children and Adolescents, 2) their MRIs were sent  for consultation from 
other hospitals in Finland, or 3) they were patients with a similar phenotype identified by 
the Departments of Pediatrics and Pathology, University of Oulu. Five of the patients 
participated in the prospective study. In addition, medical records and neuropathological 
specimens of eight patients with a similar phenotype, seven of whom were deceased, were 
reviewed.  
1.5 Ethical aspects  
Because most of the subjects were children and/or had developmental problems, they 
could not provide informed consent. Diseases of this category cannot, however, be 
investigated in any other patient group and the findings are likely to benefit both these 
subjects and future patients. Except for the blood samples for DNA studies in patients with 
18q deletions, the investigations performed had clinical as well as scientific indications.  
 
The study protocol was approved by the Ethics Committee of the Hospital for Children 
and Adolescents, University of Helsinki. All parents or patients provided written consent 
prior to investigations being performed. 
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 2. Methods 
2.1 Clinical evaluation 
A general physical examination and a neurological examination were performed by the 
author on all patients. Patients and parents were interviewed and previous clinical data 
reviewed. All patients of the Overview, Study I, and Study IV underwent an 
ophthalmologic examination.  
2.2 Neurophysiological examinations (Overview and Study I)  
Motor and sensory nerve conduction velocity (NCV) studies were available for 36 
patients. Studies of 33 patients were performed in our hospital (17 examinations during 
this study), and three studies recently performed in other hospitals were reviewed. The 
results were interpreted using age-dependent reference values from the literature (79, 92). 
The type of neuropathy was judged as predominantly demyelinating in cases with 
abnormally slow NCVs and predominantly axonal in cases with abnormally low sensory 
or motor amplitudes, or if NCV was only slightly slowed despite evidence of denervation. 
 
Somatosensory evoked potentials (SEP) of 32 patients were recorded. Thirty studies were 
performed in our hospital (27 examinations during this study), and two studies performed 
elsewhere were reviewed. SEPs were recorded with median nerve stimulation in 28 
patients and with tibial nerve stimulation in 31 patients (four limb study in 27 patients). 
Results of EEG studies were available for 37 patients. (25 studies in our hospital, 15 of 
them during this study, and 12 studies elsewhere). 
2.3 Exclusion of known white matter disorders (Overview, Study I)
Previous laboratory work-up of the patients was reviewed and complemented as needed to 
exclude, as far as possible, hereditary disorders known to be associated with white matter 
abnormalities (Table 4). If not examined previously, the following investigations were 
performed on all undiagnosed patients (or one of the siblings): basic chemical and 
hematological studies (blood count, blood gases, electrolytes, anion gap, glucose, 
transaminases, creatinine, thyroid function, calcium homeostasis, creatine kinase, 
ammonia), cholesterol, lactate, pyruvate, total and free carnitines, B12-vitamin, folate, 
very long chain fatty acids, phytanic acid, vacuolated lymphocytes, desialotransferrin, 
amino acids in plasma and urine, organic acids, oligosaccharides (including free sialic 
acid), and glycosaminoglycans in urine. Lysosomal enzyme activities to exclude MLD and 
Krabbe disease were performed on all patients except for two patients with improving 
MRI findings. For 17 patients, also lysosomal enzymes related to GM1 and GM2 
gangliosidosis were examined. If clinically indicated, further studies were performed, 
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 including blood levels of  copper and ceruloplasmine, uric acid, acylcarnitines, biotinidase 
activity, karyotype, FISH studies (to exclude 18q- syndrome or Angelman syndrome), 
pyruvate metabolism in cultured fibroblasts, muscle or nerve biopsy, respiratory chain 
enzyme activites, and DNA studies (to diagnose Salla disease, PMD, VWM, Alexander 
disease, INCL, or mitochondrial mutations and deletions). In 20 patients, CSF was 
investigated for cells, glucose, protein, lactate, pyruvate, IgG-index, oligoclonal bands and 
amino acids. An additional 13 patients had had a previous CSF study, with measurements 
of at least cells, protein, and lactate. 
2.4 Exclusion of other disorders with cerebral calcifications (Study IV) 
The extensive cerebral calcifications of patients in Study IV necessitated investigations, 
including calcium homeostasis, parathyroid function, vitamin D-25, liver function, lactate, 
pyruvate, B12-vitamin, folate, plasma amino acids, urine organic acids, and antibodies 
related to coeliac disease. 
2.5 MRI studies  
Brain MRIs were performed on a 1.5T MRI unit with at least axial T2-weighted, FLAIR, 
and sagittal T1-weighted images. In the Overview, Study I and Study IV, three patients 
had only one brain MRI study; all others had two or more MRI studies. Five patients 
(Study I) also underwent spinal MRI with sagittal T2-weighted fast spin-echo images. 
Brain MRI was performed only once in 18q- deletion patients: 15 studies were performed 
prospectively, and in seven cases previous MR images were reviewed. 
2.6 MRI classification 
MRIs were classifed using a method developed previously (133), but the subgrouping of 
Category A was slightly modified. The imaging findings were grouped into seven major 
categories according to the predominant location of the white matter abnormalities, using 
a scoring list of 68 items (Appendix 1). The categories were: 
 
A. Myelination abnormalities  
 
A1. Severe hypomyelination. No myelin visible on T2- or T1-weighted images  
 
A2. Moderate hypomyelination. No or very little myelin on T2-weighted images, but a 
substantial amount of myelin signal on T1-weighted images.  
 
A3. Other myelination abnormalities. Severely delayed (myelination age <6-8 months in 
children >12 months of age), arrested, or irregular myelination (myelination does not 
progress evenly in all cerebral lobes or zones). 
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 Table  4. Laboratory work-up in leukoencephalopathies. 
Examination  
 
Relevant in diagnosis of  
Blood  
creatine kinase mitochondrial disorders, metabolic myopathies 
ammonia urea cycle defects, organic acidurias 
lactate, pyruvate mitochondrial disorders, organic acidurias 
total and free carnitine mitochondrial disorders, organic acidurias 
B12 vitamine, folate disorders of B12 and folic acid metabolism 
very long chain fatty acids, 
phytanic acid 
peroxisomal disorders (X-ALD, Refsum disease) 
cholesterol and cholestanol cerebrotendinous xanthomatosis 
biotinidase activity biotinidase deficiency 
vacuolated lymphocytes lysosomal storage disorders (AGU, fucosidosis,  
infantile GM1 gangliosidosis) 
amino acids and homocysteine amino acidopathies, urea cycle defects,  
hyperhomocysteinemias, mitochondrial disorders 
copper, ceruloplasmine Wilson disease 
desialotransferrin CDG syndromes 
urate molybdenum cofactor deficiency 
karyotype and FISH studies chromosomal abnormalities (18q-, 11q-, 6p- deletions, 
sex chromosomal disorders, Angelman syndrome) 
CSF   
protein infantile Krabbe disease, MLD, MNGIE 
lactate, pyruvate mitochondrial disorders 
IgG index, oligoclonal bands immune-mediated diseases 
amino acids amino acidopathies (nonketotic hyperglycinemia) 
Urine  
oligosaccharides lysosomal storage disorders (Salla disease, AGU, 
GM1 and GM2 gangliosidosis, fucosidosis) 
glycosaminoglycans mucopolysaccharidoses (multiple sulfatase deficiency) 
organic acids organic acidurias (Canavan disease, L-2- and D-2-
hydroxyglutaric aciduria, glutaric aciduria), 
hyperhomocysteinemias, mitochondrial disorders, 
aminoacidopathies 
Enzyme activities in  
fibroblasts or leukocytes 
  
galactocerebrosidase 
arylsulfatase A  
 
betagalactosidase 
hexosaminidase A and B 
Krabbe disease 
metachromatic leukodystrophy, multiple sulfatase 
deficiency 
GM1 gangliosidosis 
GM2 gangliosidosis 
DNA studies 
 
e.g. Pelizaeus-Merzbacher disease, Alexander disease, 
Salla disease, VWM, INCL, deletions and mutations 
of mitochondrial DNA 
muscle biopsy  mitochondrial disorders, congenital muscular dystrophies 
nerve biopsy giant axonal neuropathy, other axonal neuropathies 
skin biopsy CADASIL, Salla disease 
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 B. Global cerebral white matter abnormalities 
• all cerebral lobes are involved 
• all cerebral white matter zones are involved, but minimal sparing 
of U-fibers is accepted 
 
C. Extensive cerebral white matter abnormalities combined with involvement of the 
putamen 
• frontal predominance or global involvement of cerebral lobes 
• not all zones of the cerebral white matter necessarily involved 
(U-fibers may be spared) 
  
D. Predominantly periventricular white matter abnormalities 
 
E. Predominantly lobar white matter abnormalities 
  
F. Predominantly subcortical white matter abnormalities 
 
G. Predominantly posterior fossa white matter abnormalities 
 
With the majority of patients being children or adolescents, clearly enlarged sulci were 
considered a sign of atrophy.  
 
MR images were reviewed simultaneously by two radiologists experienced in child 
neuroradiology (Doctors Valanne and Autti) and one child neurologist (the author), and in 
case of disagreement, a consensus of interpretation was reached by discussion. 
 
 
Figure  8. Decision tree used to categorize patients with unclassified leukoencephalopathies, 
according to van der Knaap et al. (133). 
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  2.7 Quantitative MRI signal analysis 
To strengthen the visual analysis of MRIs of patients with 18q deletions, the signal 
intensities of the white matter and of the deep gray matter were measured quantitatively on 
T2-weighted images in 11 patients and in 11 healthy, age-matched controls, using a 
previously described method (4). The measured values were related to the signal intensity 
of the CSF. Three patients under 10 years of age were excluded from the statistical 
analysis because CSF spaces of the controls were too narrow to be measured.  Mann-
Whitney U-test was used in statistical analyses. 
2.8 MRS 
MRS studies were performed  with two different 1.5 MR units. 3D proton magnetic 
resonance spectroscopic imaging (1H-MRSI) was performed on 8 patients (age 3.3-30 
years) and a single voxel spectroscopy on 12 patients (age 2-21 years). 3D MRSI 
consisted of a double spin-echo (SE) spectroscopic sequence with 16 x 16 phase encoding 
steps (repetition time [TR] 1500 ms; echo time [TE] 288 ms) and eight 10-mm slices with 
two acquisitions. Volume preselection was 100 x 100 x 80 mm3. In Study I, the white 
matter metabolite intensity was sampled as the average of eight voxels. For comparison of 
signal intensities, the spectra of individuals were corrected for coil loading and volume of 
interest (VOI) size, and values were given in institutional units. Single voxel spectra were 
measured from 8 cm3 volumes in the frontoparietal white matter, with stimulated echo 
sequences (TR 3000 ms; TE 270 ms).  
 
At the beginning of the study, the length of the MRS examination was 1.5 hours. In 
agreement with the recommendation of the local ethics committee, MRS was performed 
only on patients who did not need to be sedated. Towards the end of the study, the length 
of the MRS had considerably decreased, allowing us to prolong MRI sedation to obtain 
MR spectra. Six healthy 11- to 23-year-old controls were used for 3D measurements and 
six healthy 11- to 18-year-old controls for 1D measurements. For practical and ethical 
reasons, the examination of young, healthy children was not possible. Age-related changes 
in MRS, from the literature (96, 139), were used to assess the spectra of the younger 
children.  
2.9 Analysis of chromosome 18 deletions (Studies II and III) 
Blood samples of patients with 18q deletions and both parents, if available, were obtained 
and genomic DNA was extracted from the blood leukocytes using a standard method. The 
size of the deletion was determined using segregation analysis with microsatellite markers 
mapping to 18q. The order and location of the markers were based on those of the 
databases of the National Center for Biotechnology information (www.ncbi.nlm.nih.gov) 
and the UCSC Genome Browser (www.genome.ucsc.edu). A tetranucleotide repeat 5´to 
the myelin basic protein (MBP) gene was analyzed (MBP-STR-A/B) as previously 
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 described (94, 118). All markers were PCR amplified and for allele determination, the 
amplified DNA samples were separated on a nondenaturing polyacrylamide gel and run 
for 8000 Vh. Two patients had large regions of uninformative telomeric markers, and thus, 
a subtelomeric FISH of 18q was performed to exclude an interstitial deletion. A multicolor 
FISH was performed on one patient to exclude translocation. 
2.10 Neuropathological evaluation (Study IV) 
Six patients of Study IV were previously autopsied. Neuropathological samples were re-
examined (by Doctors Paetau and Herva), as were brain biopsies of two patients. 
Immunohistochemical stainings with antibodies against the endothelial marker CD31, the 
basement membrane marker laminin, and smooth muscle actin were performed in one. 
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 RESULTS 
1. Overview of undetermined leukoencephalopathies 
1.1. Clinical findings 
The onset of symptoms was during the first year of life in 24 patients (63%). The 
predominant symptoms at presentation (Table 5) differed between infants and older 
children. Infants presented with hypotonia, nystagmus, “progressive CP” of spastic or 
dystonic type, seizures, or “encephalopathy” (irritability, hypertonus, poor visual contact). 
Older children and adolescents, in turn, presented with ataxia, tremor, distal spasticity, 
developmental delay, or neuropsychiatric symptoms. 
 
Table  5. Predominant manifestation at presentation. 
Manifestation No. of patients (%) 
 
Spasticity or dystonia 13 (34) 
Ataxia 11 (29) 
Developmental delay +/- seizures 7   (18) 
Severe hypotonia +/- nystagmus 5   (13) 
Neuropsychiatric symptoms 2   (5) 
 
The symptoms were progressive in 27 (71%) patients. Six of them had an episode of acute 
deterioration, often in conjunction with a trivial viral infection, and recovery was only 
partial. In two patients with severe hypomyelination, the appearance of distal spasticity 
was taken as a sign of progression, even if ataxia and nystagmus had decreased. Eleven 
patients (29%) had static neurological signs. 
 
Clinical findings are summarized in Table 6. Over the course of the disease, 58% of 
patients developed spasticity and 39% ataxia. Seizures occurred initially in five of 38 
patients (13%), but epilepsy eventually affected 39% of patients. In 42% of patients, 
cognitive development was hampered early in the course of the disease and led to mental 
retardation. Learning disabilities were present in 32% of patients. In 13% of patients, 
decline in cognitive skills was evident. However, in most cases, motor problems were 
more pronounced than cognitive deficits. 
 
Ophthalmological investigation revealed squint in 21% and rotatory or pendular 
nystagmus in 16% of patients. Typically, nystagmus was severe in infancy, but 
ameliorated during the first years of life. Optic nerve atrophy was observed in three 
patients (8%), and two patients had severe visual impairment due to central deficits. Subtle 
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 irregularities of retinal pigmentation were present in three patients. One patient had severe 
myopia. 
 
Audiometry was performed during or prior to the study on 28 patients with adequate co-
operation. Three patients had sensorineural hearing impairment. One was diagnosed with 
18q- deletion, and another had MRI findings suggestive of intrauterine CMV infection. 
 
NCV studies showed signs of peripheral polyneuropathy in 11 of 36 patients (31%). The 
type of neuropathy was predominantly demyelinating in four patients and predominantly 
axonal in seven patients. SEP was abnormal in 20 of 33 patients (61%), showing low or 
absent cortical responses in 18 patients and delayed CNS conduction in 10 patients. One 
patient had asymmetric cortical responses and another had abnormally high cortical 
responses in median nerve stimulation. EEG was abnormal in 27 of 38 patients (71%). A 
background abnormality was found in 17 patients, accompanied by epileptiform 
discharges in 11 patients. Eight patients had epileptiform discharges with normal 
background activity. 
 
Table  6. Clinical findings of 38 patients with undetermined leukoencephalopathy. 
Clinical findings 
 
No. of patients (%) 
 
Truncal hypotonia 22      (58) 
Spasticity or dystonia 22      (58) 
Cognitive problems:  
  Early mental retardation 16      (42) 
  Learning disorder  12      (32) 
  Cognitive decline 5        (13) 
Ataxia 15      (39) 
Seizures 15      (39) 
Polyneuropathy 11/36 (29) 
Tremor 9        (24) 
Dysmorphic features 9        (24) 
Squint 8        (21) 
Nystagmus 6        (16) 
Optic atrophy 3        (8) 
Hearing impairment 3        (8) 
1.2 MRI classification and comparison with clinical findings 
The MRIs were classified into seven categories (Table 7). The largest groups were 
category A with abnormal myelination (53%) and category D with periventricular 
abnormalities (32%). No MRIs were grouped into categories F or G (predominantly 
subcortical or posterior fossa abnormalities). 
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 Table  7. MRI classification and established diagnoses within different categories. 
Category  No. of 
patients 
 
Established diagnoses (n) 
A1 3  Salla disease (1)  
A2 4  H-ABC (1) 
A3 13  18q deletion (1) 
B 1   
C 1  Alexander disease (1) 
D 12  LBSL (6) 
E 4   
F 0  
G 0  
Total 38  
H-ABC, hypomyelination with atrophy of the basal ganglia and cerebellum; LBSL, 
leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate 
 
Category A1. Severe hypomyelination (Figure 9). Patients with severe hypomyelination 
lacked additional lesions in MRI, only minor white matter volume loss was observed in 
follow-up. The myelin deficiency remained unchanged in repeated examinations. These 
patients presented in infancy with severe hypotonia and delayed motor development. Two 
of three patients had severe rotatory or pendular nystagmus, with ataxia manifesting later. 
Positive psychomotor development was seen in childhood with decreasing nystagmus and 
ataxia, but in two patients distal spasticity evolved (at ages of 2 and 16 years). All patients 
were mildly to moderately mentally retarded. 
  
 a b 
Figure  9. Category A1. Axial (a) and sagittal (b) image of a 4-year-old boy. White matter 
signal intensity is high on the T2-weighted image (a) and low on the T1-weighted 
image (b), consistent with severe hypomyelination. 
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 Category A2. Moderate hypomyelination (Figure 10). This group had deficient 
myelination in the cerebrum. The cerebellum showed a better state of myelination in three 
of four patients. Additional findings were cerebellar atrophy in two patients, one of whom 
also had cortical atrophy. Two patients had basal ganglia lesions (calcifications in one and 
atrophy in one patient). Clinically, all four patients in this category had slowly progressive 
neurological signs. Two of four patients presented in infancy with hypotonia, nystagmus, 
and psychomotor retardation, with a later onset of spasticity. Two patients (siblings) had 
always been clumsy. They presented at mid-childhood with ataxia and tremor, and mild 
cognitive decline became evident during follow-up.  
 
 a b 
Figure  10. Category A2. Moderate hypomyelination. Axial T2-weighted image (a) of a 17-year-
old boy shows deficient myelination. On T1-weighted images (b), the white matter 
signal is high, indicating that small amounts of myelin are present. 
Figure  11. Category A3. An axial T2-weighted image of a 
4-year-old girl shows patchy and irregular 
myelination. 
Category A3. Delayed, arrested, or irregular 
myelination (Figure 11). Both imaging and clinical 
findings were very heterogeneous in this group. In 
addition to myelination abnormality, other types of 
pathology were common. Nine of 13 patients (69%) 
had atrophic findings; cerebellar atrophy in seven and 
cortical atrophy in five patients, with white matter 
volume loss in three of them. One patient had basal 
ganglia calcifications. The most common clinical 
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 manifestations within this group were mental retardation, truncal hypotonia, spasticity, 
epilepsy, and ataxia. Two patients showed substantial progress in myelination during 
follow-up, thus representing delayed myelination. These patients had static neurologic 
signs (infantile-onset epilepsy and learning disability with dysmorphism). 
 
Category B. Global involvement of cerebral white matter (Figure 12). The MRIs of 
only one girl belonged to this group. She presented at the age of 1 month with irritability, 
developmental regression, and dystonia, subsequently developing epileptic spasms, optic 
atrophy, and demyelinating polyneuropathy. 
 
 a b 
Figure  12. Category B. Axial images of a 3-month-old girl. The cerebral white matter is globally 
hyperintense on the T2-weighted image (a) and partly hypointense on the FLAIR 
image (b), consistent with rarefaction. 
Category C. Frontal white matter involvement with basal ganglia abnormalities 
(Figure 13). This pattern is consistent with Alexander 
disease. The one child in this group presented with 
prolonged seizure, psychomotor regression, and 
spasticity at the age of 9 months. She was 
normocephalic. 
 
Figure  13. Category C. An axial T2-weighted image of a 
4-year-old girl. The white matter abnormality 
is predominantly frontal. The basal ganglia 
are atrophic and show signal abnormalities. 
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 Category D. Predominantly periventricular white matter abnormalities (Figure 14). 
Six patients in this category showed a unique imaging pattern, described in detail in Study 
I. The remaining six patients had heterogeneous MRI- and 
clinical findings, with additional basal ganglia 
abnormalities (calcifications or atrophy) in two, cortical 
atrophy in two, and cerebellar atrophy in one patient. 
Three patients had reduced white matter volume. Three of 
six patients, including two siblings, presented with acute 
neurologic deterioration during infectious disease. 
Figure  14. Category D. An axial FLAIR image shows 
hyperintensity predominantly in the 
periventricular areas. 
 
 
 
Category E. Predominantly lobar white matter abnormalities (Figure 15) without 
additional lesions elsewhere. All patients in this category 
had static neurological signs, including delayed 
psychomotor development, neuropsychiatric symptoms, 
dysmorphic features, and/or sensorineural hearing 
impairment.  
Figure  15. Category E. An axial T2-weighted image of an 8-
year-old girl shows hyperintense, patchy lesions 
in the lobar white matter. The subcortical fibers 
and periventricular areas are spared. 
 
 
 
1.3 MRS findings 
MRS was performed only once in all 20 patients studied, and thus, changes related to the 
stage of the disease could not be assessed. 1H-MR white matter spectra were normal in 
only two patients with hypomyelination (Table 8). Patients with LBSL (# 14-18 in Table 
8) showed a consistent pattern of findings, with decreased NAA and presence of lactate, 
discussed in detail in Study I. The findings of the other patients were more variable. Cho 
was increased in 10 patients, with a concomitant increase in Cr in eight patients. NAA was 
decreased in 13 patients. One patient with dysmyelination had distinct findings, with 
severely decreased Cho and mildly decreased NAA and Cr. A Lac peak was seen in eight 
patients. 
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Table  8. Findings of 1H-MR spectra from the affected white matter (long echo time). 
Patient MRI 
category 
 
Age at 
MRS  
NAA Cr Cho Lac 
1 A1 4y10m = = = - 
2 A2 3y4m ↓↓ ↑ ↑↑ + 
3 A2 12y (↑) ↑ = - 
4 A2 20y = = = - 
5 A3 4y8m (↓) (↓) ↓↓ - 
6 A3 5y10m ↓ = = - 
7 A3 8y7m = ↑↑ ↑ + 
8 A3 16y ↓↓ (↓) (↑) - 
9 C 4y ↓↓ = ↑↑ ++ 
10 D 1y9m = ↑↑ = - 
11 D 2y1m = ↑ ↑↑ - 
12 D 3y8m = ↑↑ ↑↑ - 
13 D 7y4m ↓↓ = ↑↑ - 
14 D 9y ↓ = = + 
15 D 12y ↓↓ = ↑ + 
16 D 13y ↓ = = + 
17 D 16y ↓ = = + 
18 D 30y ↓↓ = = + 
19 E 13y ↓ ↑ ↑ - 
20 E 16y ↓ ↑ ↑ - 
 
(↑)/(↓) possible increase/decrease; ↑/↓  mild increase/decrease; ↑↑/↓↓ severe 
increase/decrease 
1.4 Diagnosed cases and results of laboratory examinations 
During the study, a specific diagnosis was established in 10 patients (Table 7).  
1.  Salla disease was diagnosed in one patient (Category A1), previously missed due to 
erroneously normal findings of urinary oligosaccharides (70).  
2. One patient with hypomyelination (Category A2) developed atrophy of the putamen, 
caudate nucleus, and cerebellum, a MRI pattern consistent with H-ABC (130). 
3. One patient (Category A3) with a partial deletion of chromosome 18q was diagnosed 
using a prometaphase study and 18q subtelomere FISH. 
4. A mutation of the glial fibrillary acidic protein (GFAP) gene was found in the only 
patient in Category C, confirming the clinical diagnosis of Alexander disease. 
5. Six patients with uniform clinical and MRI findings (LBSL) are described in Study I. 
 
DNA studies for Pelizaeus-Merzbacher disease in males with severe hypomyelination 
were normal. Despite a MRI pattern consistent with VWM disease for the only patient in 
category B, no mutations of the five subunits of eIF2B genes were found. In category E, 
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 one patient had an imaging pattern highly suggestive of congenital CMV infection. She 
had also suffered neonatal thrombocytopenia and had sensorineural hearing impairment 
consistent with congenital CMV infection, but retrospectively, the diagnosis could not be 
confirmed. 
 
One patient in Category D had a homozygous SCAD (short-chain acyl CoA 
dehydrogenase) gene variation which explained her elevated urinary ethylmalonic acid, 
but whether this caused all her neurologic findings is uncertain since asymptomatic 
individuals also may carry this variation (28). 
 
Five patients in categories C and D had a slightly increased IgG index in the CSF. In 
patients with elevated lactate or pyruvate levels, further studies for mitochondrial 
disorders were inconclusive. A muscle biopsy was performed on 8 patients during the 
study and had been performed previously on 9 patients. It was normal in 10 patients, 
showed signs of neurogenic damage in three patients, and revealed mild steathosis in two 
patients. Two patients had a few clusters of compact mitochondria, warranting further 
studies of mitochondrial disorders. Sural nerve biopsies (3 patients) showed normal 
findings for one patient and axonal neuropathy for two patients. 
2. Leukoencephalopathy with brain stem and spinal cord involvement 
and elevated white matter lactate (LBSL) (Study I) 
2.1 Clinical findings 
Six patients with uniform MRI and clinical findings were identified among patients with 
undetermined leukoencephalopathies. The children learned to walk unsupported at the age 
of 10-18 months, but three of them had always had a slightly unsteady gait (Table 9). 
Neurologic symptoms manifested at the age of 3-10 years, with tremor or ataxic gait. The 
symptoms were slowly progressive. By adolescence, distal spasticity and/or deficits in 
proprioception and vibration sense were evident. In four patients, the main disability was 
due to sensory ataxia, while distal spasticity predominated in one patient. The adult patient 
had a 20-year history of symptoms. She needed support in walking since the age of 20. At 
31 years of age, she had severe sensory ataxia, but was still ambulant. In one patient (#3), 
MRI was performed at the age of 6 years because of nocturnal seizures. He was still 
asymptomatic and had a normal neurologic examination at the age of 13 years. The 
general cognitive level of the patients was normal, but three patients had learning 
problems. 
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Table  9. Clinical findings of six patients with LBSL. 
Characteristic Patient  
 
 1  2 3 4 5 6 
Affected/ 
unaffected 
siblings 
 
0/1 1/0  
(Pat. 3) 
1/0  
(Pat. 2) 
0/1 0/2  0/2 
Age/gender 
 
30/f 16/m 13/m 12/f 11/f 15/m 
Initial symptoms 
/age at onset   
 
ataxia, 
tremor/10y  
always 
unsteady, 
tremor/ 
2.5y 
seizures
/6y 
always 
unsteady, 
ataxia, 
tremor/3y 
always 
unsteady, 
ataxia, 
tremor/9y  
tremor, 
headache
/10y 
Progression of 
symptoms 
dysarthria/ 
11y 
distal 
spasticity/ 
15y 
 
ataxia, 
distal 
spasticity
/16y 
- dysarthria/ 
10y 
distal 
spasticity/ 
12y 
- ataxia, 
distal 
spasticity
/14y 
Romberg sign 
 
++ + - + + (+) 
Sensory function vibration 
sense↓/16y 
 
vibration 
sense↓/ 
16y 
normal vibration 
sense ↓↓ 
position 
sense ↓ 
 
vibration 
sense↓ 
position 
sense↓ 
normal 
Deep tendon 
reflexes 
 
↑ 
 
↑ normal ↓ ↑ ↑ 
Babinski sign +/13y 
 
+/16y - +/12y - +/14y 
Cognitive 
function 
visuo-
spatial 
deficits 
normal normal learning 
problems  
normal visuo-
spatial 
deficits 
Axonal 
neuropathy 
+ - - + + + 
Medianus SEP low 
cortical 
responses 
normal normal normal normal normal 
Tibialis SEP delayed 
central 
conduction 
low 
cortical 
responses 
normal delayed 
central 
conduction 
delayed 
central 
conduction 
normal 
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 2.2 Neurophysiological findings  
Nerve conduction examination was mildly abnormal in four of six patients (Table 9), 
consistent with predominantly sensory axonal neuropathy in three of them and 
predominantly motor axonal neuropathy in one patient. SEPs with tibial nerve stimulation 
showed delayed central conduction in three patients and low cortical responses in one. 
SEPs with median nerve stimulation were normal, except in one patient who had low 
cortical amplitudes. Two patients had midtemporal spikes in EEG; in the others, EEG was 
normal. 
 
2.3 MRI and MRS findings 
All patients had lesions in periventricular and deep white matter. They were hyperintense 
in both T2 and FLAIR images and varied from patchy and inhomogeneous to confluent. 
The subcortical U-fibers were spared. The posterior limbs of the internal capsules and 
corona radiata were affected in all patients and the posterior part of the corpus callosum in 
five patients, while the anterior part was totally or mostly spared. The subcortical 
cerebellar white matter was affected in four patients.  
 
In the brainstem, the pyramidal tracts, mesencephalic trigeminal tracts, and superior and 
inferior cerebellar peduncles were involved, and in some cases also the anterior 
spinocerebellar tracts and transverse pontine fibers. In follow-up, the brainstem 
abnormalities progressed slightly in three patients, and minor white matter volume loss 
occurred in two patients. 
 
The spinal cord was hyperintense in T2-weighted images. In two patients with axial 
images, this hyperintensity could be localized to the dorsal columns and to the lateral 
corticospinal tracts.  
 
In all five patients studied by 1H-MRS, the frontoparietal white matter spectra showed 
elevated Lac, reduced NAA and normal Cr. Cho was elevated in only one patient. Cortical 
and thalamic gray matter spectra were normal.  
3. Deletions of chromosome 18q (Studies II and III) 
3.1 Clinical findings in patients with terminal and interstitial deletions of 18q (Study III) 
The phenotype of patients with 18q deletions was highly variable. The clinical findings are 
summarized in Table 10 and presented in detail in Study III. Among common problems in 
infancy were hypotonia, delayed psychomotor development, nystagmus, recurrent 
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 respiratory infections, and atopic disorders. Most patients had slightly dysmorphic facial 
features and deformities or anomalies of the hands or feet. Half of the patients had  atresia 
or stenosis of the external auditory canals, and 43 % had hearing impairment. During 
childhood, common problems were motor clumsiness, wide-based gait, poor coordination, 
and difficulties in balance and visuomotorics. Only a few patients had epilepsy with 
complex partial and generalized seizures. Cognitive function ranged from normal IQ to 
severe mental retardation. The two affected parents had visuo- and fine motor deficiencies, 
but IQ within the normal range. The neurologic symptoms were nonprogressive. 
 
EEG had been performed on 11 individuals. Three had epileptiform activity and five had 
minor background abnormality. Motor and sensory conduction velocities of the peripheral 
nerves, investigated in two patients, were normal despite very weak deep tendon reflexes. 
 
Table  10. Most common clinical features in patients with terminal and interstitial 18q 
deletions. 
Feature 
 
No. of 
patients  
Small for gestational age 7/14 
Height below –2 SD 7/14 
Facial dysmorphism (flat midface, down-turned 
corners of mouth, malformed earlobes, 
hypotelorism, short neck) 
12/14 
Aural atresia/stenosis 7/14 
Palatal abnormalities (cleft lip/palate, bifid uvula) 4/14 
Cryptorchidism or micropenis 5/8  
Hand anomalies (proximal thumbs, tapering 
fingers) 
9/14 
Foot deformities (overriding toes, club foot, pes 
cavus, vertical talus) 
8/14 
Hyperextensible joints 6/14 
Hernias (umbilical or inguinal) 4/14 
Frequent respiratory tract infections 8/14 
Atopic disorders 8/14 
IgA deficiency 2/7  
Motor clumsiness/dyscoordination 12/14 
Hypotonia 10/14 
Dysmyelination 10/14 
Mental retardation 8/14 
Weak/absent deep tendon reflexes 7/14 
Nystagmus 6/14 
Hearing impairment 6/14 
Oral dyspraxia 5/14 
Squint 4/14 
Autistic features 4/14 
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 3.2 Phenotypic variation within families 
Interestingly, manifestations of 18q- deletions varied between members of the same 
family, as demonstrated by Family I (Table 11). Despite similar-sized deletions, the 
presence of e.g. palatal and aural abnormalities, foot deformities, and mental retardation 
was variable. However, the dysmyelination phenotype did not vary within families. 
Evidence for mosaicism, which could explain this variation, was not detected in 50 
analyzed metaphases of the mother.  
 
Table  11. Phenotypic variation within a family (Family I, Study III) 
Feature 
 
Son Son Mother 
Age, years 2.8 12 36     
Height, SD -2.5 -1.8 -2.8 
Facial dysmorphism             + + — 
Aural atresia/stenosis                + + — 
Cleft lip/palate or bifid uvula + + — 
Hand anomaly  + + — 
Foot deformity                      — + + 
Umbilical or inguinal hernia — + + 
Atopic disorders                  + + + 
Hypothyreosis — — + 
Dyscoordination                  + + + 
Hypotonia                              + + — 
Dysmyelination  + + + 
Mental retardation ++ ++ — 
Nystagmus                             + + + 
Hearing impairment                  + + — 
Strabismus                             + + + 
Autistic features                    — + — 
Tremor                                   — — + 
 
3.3 MRI findings (Studies II and III) 
Myelination was abnormal in 18 of 22 patients: in all patients with terminal 18q-deletions 
and in one patient with an interstitial 18q deletion. In the youngest patient (aged 8 
months), this appeared as severely delayed myelination. In older children and adults, the 
cerebral white matter was diffusely hyperintense on T2-weighted images, which led to 
poor differentiation of gray and white matter. A topographical variation in the extent of 
myelination was observed; lower frontal and temporal areas were better myelinated than 
upper frontal, parietal, and occipital areas. Moreover, 72% of the patients (13/18) had T2 
hyperintensity in the posterior limbs of the internal capsules, and 67% (12/18) had poor 
differentiation of the cerebellar gray and white matter. Mild atrophic findings were seen 
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 supratentorially in three and infratentorially in three patients. Additional findings present 
in single patients were a porencephalic cyst and a focal mass lesion. 
 
The abnormality of the signal intensity, observed in visual analysis, was confirmed by 
quantitative measurement of signal intensities. The measured signal intensities of the 
occipital and frontal white matter were significantly higher (p=0.0008) in the patients than 
in the controls. Signal intensities of the caudate nuclei, putamina, and thalami were also 
significantly increased in patients (p=0.0157, p=0.0063, p=0.0016, respectively). 
 
Four patients with interstitial deletions (Family II and Patient 14) had a normal 
myelination pattern in MRI. In one of them, a few nodular periventricular heterotopias 
were observed. 
3.4 Molecular study – size of deletions and comparison with phenotype (Study III) 
In two patients, who cytogenetically appeared to have terminal deletions, molecular study 
showed heterozygosity for the distal markers of 18q. This implies that they had interstitial 
deletions. The size of the deletions varied from 7.7 Mb to 29.4 Mb, and only a small 
common region (approximately 1.1 Mb) was deleted in every patient.  
 
In phenotype-genotype comparison, the patients with unbalanced translocations were 
excluded. All patients with an interstitial deletion and normal myelination spared a region 
between markers D18S469 (69.5 Mb) and D18S1141 (75.0 Mb). This area was deleted in 
every patient with abnormal myelination. This critical region for dysmyelination includes 
the gene for MBP, which was specifically tested.  
 
Individuals with atretic or stenotic auditory canals, palatal abnormalities, nystagmus, and 
IgA deficiency shared deletions between markers D18S812 (68.4 Mb) at q22.3 and 
D18S1141 (75.0 Mb) at q23. Individuals with cryptorchidism shared a deletion between 
markers D18S64 (55.6 Mb) at q21.32 and D18S469 (69.5 Mb) at q22.3. Results of the 
molecular analysis of the key patients in determining the critical area for dysmyelination 
are illustrated in Figure 16. More detailed information about segregation analysis is given 
in Study III.  
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Figure  16. A schematic presentation of 18q deletions of 22 patients, assessed by molecular 
analysis (left side of the figure). The Roman numerals refer to families (Family I: 
Patients 1-3; Family II: Patients 10-12; Family III, Patients 15-18 and Family IV, 
Patients 19-21) and the Arabic numerals to individual patients. The results of 
segregation analysis of the key patients in determining the critical region for 
dysmyelination (region A, between markers D18S469 and D18S1141) are presented 
on the right side of the figure. Myelination was abnormal in all patients, except in 
Patients 10-12 (Family II) and Patient 14. A closed circle indicates that marker 
alleles from both parents segregated to the patient (i.e. no deletion). An open circle 
indicates that only one allele segregated to the patient (deletion), and a dash 
indicates that segregation of the marker was uninformative in the family.  
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 4. Leukoencephalopathy with calcifications, cysts, and retinal vascular 
abnormalities (Study IV) 
4.1 Family history 
The study included 13 patients from 11 families. The patients had altogether 18 unaffected 
siblings. Patients 3 and 4 (siblings) had a stillborn brother with severe intrauterine growth 
retardation (IUGR). In addition, the brother of Patient 7 was born on the 31st week of 
gestation with severe IUGR and had several anomalies (radius aplasia, missing thumbs, 
syndaktylias, meatus atresia, cleft palate, and cataracts). He died on the first day of life 
due to respiratory distress syndrome and intracranial hemorrhage. The parents were 
healthy and nonconsanguineous. A segregation analysis has not yet been carried out. 
4.2 Clinical findings  
The patients showed a spectrum of neurological, ophthalmological, skeletal, 
gastrointestinal, and hematological findings, which are summarized in Table 12.  
 
Eleven of 13 patients suffered from IUGR, and five were born by Cesarean section due to 
poor growth, placental ablation, Rhesus immunization, or abnormal cardiotocography. 
One patient (#7) had malformations (patent ductus arteriosus, meatal atresia, cleft lip, 
rudimentary thumbs, and syndactyly). 
 
The patients presented at the age of 6 months to 14 years  with ophthalmological or 
neurological symptoms. The most common ocular complaints, squint, decreased vision, 
leukocoria, and painful eye were related to vitreoretinal bleeding, retinal detachment, and 
glaucoma. Neurologic presentation was with either seizures or spasticity. 
 
The most common neurological symptoms were partial epilepsy, hemiparesis, ataxia, and 
cognitive decline. In some cases, enlarging cysts caused increased intracranial pressure 
and needed shunting. Two patients had migraine-like headaches. The symptoms were 
slowly progressive. In eight patients who had been followed-up for more than 10 years, 
the disease had progressed to severe spasticity, bulbar symptoms and anarthria within 11-
20 years.  
Eleven patients had anomalies of retinal vasculature, bilaterally in nine cases. In eight 
patients, these were angioma-like excrescences of small vessels which caused preretinal 
and vitreous hemorrhages. Seven patients had retinal telangiectasias, often associated with 
subretinal lipid exudation reminiscent of Coats’ disease. In all five prospectively studied 
patients, the retina peripheral to the angiomatous nodules and telangiectatic vessels was 
avascular. Eight patients developed retinal detachment, six patients neovascular glaucoma, 
and three patients complicated cataracts. These changes led to uni- or bilateral blindness in 
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 nine patients. The retinal vasculature appeared normal in two patients with adolescence-
onset symptoms.  
 
Table  12. Characteristics of 13 patients with leukoencephalopathy and cerebral 
calcifications. 
 
 
Patients 
Early onset                                                                                         Late onset 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 
 
Gender 
 
f f m f f m f f f m f m m 
Age at  
onset, y   
 
0.9 0.5 0 0.5 0.5 5.0 0.6 1.0 1.0 2.0 4.0 14 14 
Present age, y 
(age at death) 
 
6 4 (5) 10 (13) (16) (20) (22) 20 (27) (19) 16 (43) 
IUGR 
 
+ + + + + + + + + + - + na 
Cerebral 
calcifications  
 
+ + + + + + + + + + + + + 
Leuko-
encephalo-
pathy 
 
+ + + + + + + + na + + + + 
Intracranial 
cysts 
 
- + + + - - + - - - - - + 
Retinal 
angiomas or 
telangiectasias 
 
+ + + + + + + + + + + - - 
Sparse hair 
 
+ + - - - + + + + - na - - 
Skeletal 
changes 
 
- + na - + + + + + + na + na 
Intestinal 
bleeding 
 
- - - - + + - + + + + - - 
Hematologic 
abnormality 
 
- - - - + + - + + + + - - 
Neuro-
pathological 
examination 
- - + -/ 
bb 
+ + - + - + + - -/ 
bb 
 
 aonly computed tomography (CT) available; na, data not available; bb, brain biopsy only 
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 Two of 11 patients with IUGR reached normal growth postnatally. Three patients showed 
some catch-up growth, after which the height and proportional weight increased linearly 
2-3 SD and 15-30% below the mean, respectively. In six patients, growth velocity 
gradually slowed from the age of 2-14 years, and the last growth measured had declined to 
3-5.5 SD below the mean.  
 
Six patients developed severe anemia and needed blood transfusions since the age of 11-
20 years. The underlying cause of the anemia remained obscure. Anemia was 
hypochromic and macrocytic. Bone marrow examinations, performed on four patients, 
showed increased erythropoiesis, and, in three patients, megaloblastic changes were seen. 
One patient had fragmented erythrocytes, suggestive of  mechanical hemolysis due to 
microangiopathy. Three  patients also had thrombocytopenia, which resolved after 
splenectomy.  Occult intestinal bleeding probably partly caused iron deficiency because 
recurrent intestinal bleeding began in these six patients within a few years. Endoscopies 
revealed no obvious reason for the bleeding, but showed mild inflammatory changes and, 
in one patient, partial villous atrophy. However, in another patient gut biopsy revealed 
telangiectatic vessels. Two patients developed hepatic insufficiency and esophageal 
varices.  
 
Patient 3 died unexpectedly during sleep at the age of 5 years. He had suffered prolonged 
apneic epileptic seizures, which possibly was the cause of death. Seven patients died at the 
age of 13-43 years. The immediate cause of death of these severely handicapped patients 
was pneumonia, fulminant intestinal bleeding, or multiorgan failure. 
4.3 Radiological findings  
The most striking radiological findings were extensive brain calcifications. They involved 
the thalami, the cerebral white matter, and the brain stem of all patients, and the basal 
ganglia of all but one patient. Calcifications of white matter were predominantly situated 
subcortically. The cerebellar white matter was affected in eight patients and the dentate 
nuclei in the five oldest patients. Calcifications were evident both in CT and in MRI, 
especially in T2*-weighted images, but also in T2- and T1-weighted spin-echo images. 
The brain CT performed on two patients during the neonatal period was normal.  
 
Diffuse or patchy white matter changes, hyperintense on T2-weighted MRI images, 
occurred most commonly in the periventricular region, but sometimes extended 
subcortically. The internal capsules were always involved. Brain stem lesions were seen in 
eight patients, and the cerebellar white matter and the corpus callosum were involved in 
six and four patients, respectively. All patients had signal changes in the thalami and four 
patients in the basal ganglia. In some cases, the lesions spread along the white matter 
tracts, resembling vasogenic edema, and these changes partly resolved during follow-up.  
 
Contrast enhancement appeared at the outer margin of the abnormal white matter and 
around the calcified lesions in the thalami and the basal ganglia. Five patients had 
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 parenchymal cysts, either singly or multilobularly. They were situated mainly in the 
thalamic region, but occurred also in the brain stem and in the parietal and frontal lobes. In 
some cases, the cysts appeared several years after presentation, and new cysts formed 
during follow-up.  
 
Various skeletal changes in radiographs were found in six of seven patients. Five patients 
had metaphyseal changes, including sclerosis and mild flaring, which were most 
pronounced in the distal femur and proximal tibia. The long bones appeared osteopenic in 
six patients. Additional findings in some patients were short femoral neck, abnormal 
molding of the ulna and radius, thin fibula and humerus, mild vertebral end plate 
deformity, and subnormal widening of the interpeduncular distance in the lumbar spine. 
One patient had hypo- or aplasia of the first metacarpal bones and the thumbs, hypoplasia 
of the 4th right metatarsal bone, and fusion of 4th and 5th left metatarsals. Two patients 
had pathological fractures. The areal bone mass density was reduced in all three patients 
studied. The Z-scores for the lumbar spine were -2.0, -1.8, and -1.2, and those for the left 
femoral neck were -0.5, -1.1, and -1.7. 
4.4 Laboratory findings  
The hematological abnormalities were described above. With respect to the etiology of the 
calcifications, the laboratory findings were uninformative (details in Study IV). 
Investigations of calcium homeostasis and parathyroid function, serologic studies for 
Toxoplasma and Cytomegalovirus, and karyotype (five patients) as well as mitochondrial 
work-up: blood and CSF lactate and pyruvate, urinary organic acids, muscle biopsy (three 
patients), activities of respiratory chain enzymes, and mutation analysis of the 
mitochondrial DNA (two patients) were particularly unrevealing. 
4.5 Neuropathology  
All autopsied patients had similar findings, with only variation in the extent of changes. 
Calcifications were seen along the walls of small vessels both in the deeper cortical 
laminae and in the white matter and deep nuclei. In subcortical and gyral white matter, the 
extensive calcifications often followed the shape of the U-fibers. Massive calcifications 
were seen in the thalami, basal ganglia, pontine basis, and in dentate nuclei. A very typical 
finding was a cystically degenerated focus with calcified obliterated vessels at the border 
between the pontine tegmentum and basis. Within the calcified areas, numerous small 
vessels showed thickened, hyalinized walls. Their lumina were substantially reduced or 
obliterated, and the internal elastic membrane could not be seen in the abnormal vessels. 
Angiomatous proliferation of these vessels was present in severely affected areas. 
Immunohistochemical stainings with antibodies against the endothelial marker CD31, the 
basement membrane marker laminin, and smooth muscle actin showed that the hyalinized 
thickening of the vessel walls was mainly outside the subendothelial basement membrane. 
The partly degenerated and fragmented vascular smooth muscle fibers were displaced 
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 peripherally. The white matter surrounding these lesions showed rarefaction, gliosis, and 
myelin loss. In areas devoid of vascular changes, the white matter appeared intact. No 
changes consistent with inflammation or infection were found. Gliosis and similar thick-
walled vessels were seen in brain biopsies from tissue around the cyst during 
neurosurgical operations (Patients 4 and 13). 
4.6 Other autopsy findings 
 
Two of the six autopsied patients had abnormalities of intestinal vasculature, including 
distinct nodules with thick-walled vessels or dilated vessels. In two patients, arteries of the 
portal area were thick-walled, one patient had hepatic cirrhosis, and one had a small liver. 
Two patients had mild glomerular sclerosis.  
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 DISCUSSION  
1. Overview 
1.1 Types of leukoencephalopathies found 
Childhood-onset cerebral white matter disorders are a heterogeneous group of rare 
diseases. Even though this study cannot be considered epidemiologic, the data allow some 
conclusions to be drawn on occurrence of “new” recognizable phenotypes among 
undefined leukoencephalopathies in Finland. LBSL was the most common group in 
patients entering the study due to undetermined leukoencephalopathy, thus appearing to be 
among the more common childhood-onset leukoencephalopathies in our country. More 
cases will likely be identified as awareness of this disorder increases. 
 
Vanishing white matter disease has been estimated to be among the more prevalent 
leukoencephalopathies elsewhere, with an incidence similar to MLD (1:40 000) (125). 
However, no patients with VWM were found in this study. Only one child had an MRI 
pattern suggestive of VWM disease but she did not have mutations of genes related to 
VWM. This phenotype thus seems to be rare in Finland. 
 
Leukoencephalopathy with calcifications, cysts, and retinal vascular abnormalities is 
considered a very rare disease. Thirteen Finnish patients with this phenotype, born within 
the last five decades, were identified in Study IV. Compared with the approximately 15 
similar patients previously reported in the literature, this disorder appears to be more 
prevalent in Finland than elsewhere.  
 
Other leukoencephalopathies, diagnosed in single patients were Alexander disease, 18q- 
deletion, and H-ABC. We also found one case of Salla disease, missed in previous studies. 
1.2 Usefulness of MRI categorization 
Categorization of MRI findings in patients with undetermined leukoencephalopathies 
helps in planning the most appropriate etiologic investigations. Examples of known 
disorders within each category are given in Table 13 [reviewed in (133)]. 
 
Few diseases are known to produce a pattern of severe hypomyelination. The classical X-
linked disease causing hypomyelination in males is Pelizaeus-Merzbacher disease. In 
Finland, however, exclusion of Salla disease belongs to the first line of investigations. In 
Salla disease, most patients have only supratentorial hypomyelination, but some patients, 
like the one diagnosed in this study,  may have severe hypomyelination involving also the 
cerebellar white matter (59, 70, 112). Recently, mutations in a gene encoding GJA12, a 
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 gap junction protein, were found in patients with severe hypomyelination (122). In 
addition to symptoms typical of all hypomyelinating disorders, hypotonia and nystagmus, 
these patients had facial weakness. GJA12 mutations were not excluded in our patients. 
Severe hypomyelination may also be seen in trichothiodystrophy, which clinically differs 
from the above-mentioned disorders, with characteristic congenital ichtyosis and brittle 
hair (91, 95). In H-ABC disease, severe or moderate hypomyelination is accompanied by 
atrophy of the cerebellum and basal ganglia, especially the putamen (130). The atrophic 
findings develop gradually, emphasizing the importance of follow-up imaging. At present, 
diagnosis is based on MRI.  
 
In patients with mild to moderate hypomyelination, severely delayed myelination or 
irregular myelination, a much wider diagnostic approach must be considered. A large 
variety of metabolic disorders, such as amino acidopathies and organic acidurias (30, 93), 
fucosidosis (125), AGU (3), Cockayne syndrome (66), and biotinidase deficiency (49), 
may interfere with myelination. In addition to primarily white matter disorders, early-
onset neuronal degenerative disorders may disturb myelination (23, 48, 141) .In patients in 
category A3 who developed severe cerebral atrophy in follow-up, an underlying neuronal 
disorder is likely. Diagnosing patients with chromosome 18q deletions in this category is 
important to avoid unnecessary extensive metabolic investigations. In particular, 18q- 
syndrome should be sought in patients with dysmorphic features, meatal atresia, or poor 
growth (Studies II and III). It is noteworthy that small terminal deletions and deletions 
caused by unbalanced translocations may be missed even with high-resolution G-banding. 
In these cases, subtelomeric FISH of 18q, array CGH (comparative genomic 
hybridization), or molecular analysis may be used to establish the diagnosis. Acquired 
disorders, e.g. B12 deficiency and hypothyroidism, may also interfere with the process of 
myelination (74, 106).  
 
Global involvement of cerebral white matter is seen in a few diseases. MLC is a disorder 
characterized by macrocephaly and subcortical cysts (137). VWM disease shows typical 
findings, with cystic rarefaction of the white matter (135). Globally affected, swollen 
white matter may also be seen in merosin-deficient congenital muscular dystrophy (22). 
 
Predominantly frontal white matter abnormalities in conjunction with basal ganglia signal 
changes are typical of Alexander disease, which today can be confirmed using genetic 
methods (16, 17, 132). 
 
Many leukoencephalopathies initially involve predominantly the periventricular white 
matter. This pattern is seen, for instance, in LBSL [Study I, (128)], MLD (93), X-ALD 
(71), and some hyperhomocysteinemias (97). Increased periventricular signal is also seen 
in some patients with Angelman syndrome (personal observation). Because patients with 
Angelman syndrome present with ataxia, a symptom typical of leukoencephalopathies, 
this MRI finding may misdirect the investigations to metabolic diseases. 
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 Table  13. Examples of known diseases within MRI categories A-G (for definition of 
categories, see p.32)  
MRI category Examples of disorders within the category 
 
A1 (A2) Pelizaeus-Merzbacher disease, Salla disease, trichothiodystrophy, 
mutations in a gene encoding GJA12, H-ABC, Cockayne syndrome 
 
(A2) A3 18q- deletions, amino acidopathies, organic acidurias, galactosemia,  
fucosidosis, AGU, infantile-onset neuronal degenerative disorders 
 
B MLC, VWM, merosin-deficient congenital muscular dystrophy 
 
C Alexander disease  
 
D LBSL, MLD, X-ALD 
 
E Chromosomal disorders, congenital CMV infections 
 
F Kearns-Sayre syndrome, Canavan disease, L2- and D2-hydroxyglutaric 
aciduria 
 
G Adrenomyeloneuropathy, cerebrotendinous xanthomatosis 
 
 
 
 
Isolated, multifocal, or confluent lobar white matter lesions are seen, for instance, in 
conjunction with several chromosomal abnormalities (40, 89, 145) and in congenital CMV 
infections. 
 
Predominant involvement of the subcortical white matter is rare. It occurs in cerebral 
organic acidurias L2-and D2-hydroxyglutaric aciduria and Canavan disease (60, 108), and 
in Kearns-Sayre syndrome (69). This pattern should not be confused with delayed 
myelination presenting with unmyelinated subcortical white matter.  
 
Finally, when the lesions are located predominantly in the cerebellar white matter, 
adrenomyeloneuropathy (71, 93) and cerebrotendinous xanthomatosis (33) should 
primarily be considered. 
 
Often MRIs taken early in the course of the disease are most useful in showing the specific 
patterns of involvement. In some cases, only follow-up images reveal  the characteristic 
features, as in H-ABC, discussed above. Early- and late-onset forms of diseases may have 
different MRI manifestations, e.g. the childhood cerebral form of X-linked 
adrenoleukodystrophy shows characteristic parieto-occipital periventricular changes, 
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 while later onset adrenomyeloneuropathy may present with  abnormalities of the 
cerebellar white matter and corticospinal tracts (125).  
 
The MRI categories differed with respect to clinical manifestations. While patients with 
severe hypomyelination presented in infancy, the patients with periventricular lesions 
usually presented in childhood or adolescence  An “encephalitis-like” presentation was 
most commonly seen in patients with periventricular lesions. One-third of all patients had 
static neurologic signs, and this was most common in Category E, with isolated lobar 
changes. Many chromosomal disorders and congenital CMV infection are known to 
produce lobar white matter changes, and our patients in category E may have had some of 
these disorders, although the diagnosis could not be verified. Milder disorders with static 
signs might be underrepresented in this study because patients sent for consultation from 
other hospitals most probably represented the more severe and progressive cases in the 
spectrum of undetermined leukoencephalopathies. 
1.3 Usefulness of MRS investigations 
Not surprisingly, the MRS findings were heterogeneous in patients with unknown 
leukoencephalopathy and revealed mostly process-related abnormalities reflecting active 
myelin turnover and axonal loss within the affected white matter. We found no disease-
specific metabolic patterns, like increased NAA, consistent with Canavan disease (2) or 
peaks, which are not normally present, such as those seen in maple syrup urine disease 
(57). Half of the patients (Overview) had findings suggestive of active ongoing 
demyelination, often with concomitant gliosis. Also two patients (siblings) in category E, 
who had clinically stable disease, had slightly abnormal MRS findings, suggesting low-
grade demyelination. 
 
In hypomyelinating disorders, MRS findings of normal or decreased Cho have been 
reported previously (39, 53, 85, 95). In this study, variable findings were observed. Three 
of four patients with severe or moderate hypomyelination (categories A1 and A2) had 
normal Cho concentration and normal or near-normal NAA concentrations, arguing 
against active demyelination. In one patient with hypomyelination plus severe atrophic 
findings, MRS was suggestive of active demyelination and axonal loss. Interestingly, only 
one girl with irregular myelination (Figure 11) had severely decreased Cho, which could 
be due to a profound disturbance of myelin build-up, similar to that seen in PMD (53). 
 
Evidence for  axonal injury within the white matter was found in 65% of  patients. While 
in demyelinating disorders reduced NAA occurs late in the course of the disease, in LBSL 
(Study I) evidence for axonal injury was the initial finding and only one patient showed 
signs of demyelination (increased Cho). This suggests a different pathophysiology, with 
primary axonal involvement. All LBSL patients had elevated Lac, discussed further 
below. Highly elevated Lac was also seen in a patient with Alexander disease, consistent 
with previous findings (17). The finding of Lac in MRS warrants work-up for 
mitochondrial disorders, including muscle biopsy. However, elevated Lac is not specific 
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 to mitochondrial disorders, also being related to active demyelination, inflammation, and 
tissue necrosis (11, 73).  
 
We used mainly long echo time spectra, which are more reliable when quantitation of 
peaks is important, as in assessment of brain maturity or brain injury. However, more 
peaks are identified in short echo time spectra, which has proved to be more informative in 
neurometabolic disorders (5, 20, 80, 134), and this might have yielded more useful data in 
our study patients. MRS findings may also depend on the stage of the disease, and 
longitudinal studies were not performed. Furthermore, the lack of young control patients 
hampers the interpretation of our MRS data and may make the results less valid. 
Obviously, more thorough MRS studies are needed in the future for this patient group. 
1.4 Usefulness of other clinical and neurophysiological investigations 
In addition to careful neurologic investigation, ophthalmologic examination proved to be 
important. Nystagmus, optic atrophy, and squint occurred relatively often in patients with 
undetermined leukoencephalopathy (Overview). Fundus examination of  patients with 
cerebral calcifications is especially important because it may reveal retinal angiomas and 
telangiectasias, as was seen in patients in Study IV, or cataracts and pigmentary 
retinopathy typical of Cockayne syndrome (84).  
 
Measurement of nerve conduction velocities is necessary because clinical signs of 
peripheral neuropathy may be overshadowed by spasticity and neuropathy may exist 
despite brisk deep tendon reflexes. Even though in classical leukodystrophies the 
neuropathy is typically demyelinating, patients in the present study (Overview, Study I) 
more often had findings suggestive of predominantly axonal polyneuropathy. 
Somatosensory evoked potentials were abnormal in the majority of  patients with 
undetermined leukoencephalopathies, showing delayed CNS conduction or absent cortical 
reponses. Abnormal SEP correlated well with clinically evident sensory disturbance.  SEP 
with tibial nerve stimulation showed abnormalities more frequently and earlier than SEP 
with median nerve stimulation, probably because the measured sensory tract is longer in 
tibial SEP. While in Pelizaeus-Merzbacher disease markedly prolonged cortical latencies 
or absent cortical responses are a consistent finding (86), the two males with PMD-like 
severe hypomyelination (but without PLP mutations) in this study had normal SEP. Thus, 
in hypomyelinating disorders, a normal tibial SEP is suggestive of a diagnosis other than 
PMD. 
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 2. Leukoencephalopathy with brain stem and spinal cord involvement 
and elevated white matter lactate (LBSL)  
A specific MRI pattern and consistent clinical features defined this disorder. This disease 
was first reported by van der Knaap et al. in 2003 (128), but the pattern was found 
independently in this study, confirming that this is a separate entity with constant findings.  
 
In this disorder, designated as LBSL, the hemispheric patchy or confluent white matter 
abnormalities are combined with involvement of selective brain stem and spinal cord 
tracts. On a systemic level, the long sensory tracts (dorsal columns, medial lemniscus, and 
corona radiata) and the pyramidal tracts (internal capsules, pyramidal tracts in the brain 
stem, and lateral corticospinal tracts within the spinal cord) are involved over their entire 
length. 
 
Clinical correlates of this involvement are sensory ataxia, tremor, and impaired vibration 
sense and proprioception. Distal spasticity is usually less prominent, but in some patients 
it may be a predominant problem. The symptoms manifest from early infancy to 
adolescence and are slowly progressive. The clinical impression of dorsal column 
dysfunction was supported by evoked potential studies, which showed impaired central 
conduction of the sensory stimuli. A new finding was development of a mild axonal 
neuropathy, shown by NCV studies. 
 
The etiopathogenesis of this disease is unknown. The MRS findings might give some 
clues. MRS showed consistently elevated Lac, normal or elevated Cho, and decreased 
NAA in the abnormal white matter, consistent with a previous report. Van der Knaap et al. 
(128) proposed that axonal degeneration could be a primary pathology because the entire 
long motor and sensory tracts are involved and there is a consistent loss of NAA. 
Increased Cho, suggesting demyelination, was only occasionally found and might be 
secondary to axonal disease. The constant elevation of  Lac is also interesting and could 
point towards a mitochondrial disorder. This is supported by mild exercise intolerance and 
worsening of symptoms during infections, features reported by several patients. Also NCV 
studies suggested development of axonal neuropathy, a feature seen in several 
mitochondrial disorders (87, 140). Even though the muscle histology and respiratory chain 
enzyme complex activities were normal, a mitochondrial etiology remains a possibility. 
However, apart from mitochondrial disorders, elevated Lac is seen in MRS with several 
white matter disorders, e.g. in  Alexander and Krabbe disease (17, 18) and in MS, where it 
is related to active demyelination and inflammation (11). 
 
Our patients possibly represent an autosomally recessively inherited disease entity because 
there were affected siblings and patients were of both sexes, born to healthy parents.  
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 3. Deletions of chromosome 18q 
The 18q- syndrome is an example of a static disorder among leukoencephalopathies. The 
phenotype in patients with 18q deletions was variable, consistent with previous reports 
(26, 113). This clinical heterogeneity is partly due to variation in the size of the deletions. 
However, with respect to most clinical manifestations, the phenotype varied between 
patients with deletions of apparently similar size and even between members of the same 
family. Thus, other factors, such as effects of other genes, allelic variation of the haploid 
portion of 18q, or environmental variables, also modulate the phenotype. Moreover, 
imprinted genes in the region might influence the phenotype, but a previous study found 
no evidence supporting this in 18q- deletions (75). 
 
With regard to dysmyelination phenotype, the situation was more straightforward. A 
uniform MRI pattern – a poor differentiation of gray and white matter, consistent with 
dysmyelination – was found in all patients with deletions of the critical region in 18q22.3-
18q23. In infants, this appeared as severely delayed myelination. This phenotype was 
absent in all patients retaining that region. The region associated with dysmyelination was 
approximately 5.5 Mb. One previous study, where a single patient with an interstitial 
deletion had a normal MRI, delineated this critical region to an even smaller area of 2 Mb 
(41). The four patients in our study, who had normal brain myelination and interstitial 
deletions, spared the same 2 Mb region, confirming that result. This critical region 
includes several genes, of which the MBP gene is the logical candidate for the 
dysmyelinating phenotype because it is a major protein of CNS myelin, important for 
myelin formation and compaction (8). However, this remains to be proved, as no patient 
with a deletion of exclusively the MBP gene is known. Growth hormone deficiency, found 
to some degree in 72% of the 18q- children (51), has also been proposed to contribute to 
dysmyelination in combination with  hemizygosity of MBP (25). This dysmyelination 
pattern differed from white matter abnormalities reported in other chromosomal 
abnormalities, where focal isolated or confluent hyperintense white matter lesions on T2-
weighted images are typical findings (40, 89, 145). 
 
We also searched for any correlation of other phenotypic features with the size and 
localization of the deletion, but due to the small number of patients, no firm conclusions 
can be drawn. However, congenital atresia or stenosis of the external ear canals was found 
in 50% of the cases and was associated with deletions between markers D18S812 (at 
18q22.3) and D18S1141 (at q23). This finding is consistent with two recent reports (35, 
142), which, using array CGH, defined the critical region for congenital aural atresia to be 
located on 18q22.3-23. The gene responsible for aural atresia is unknown. 
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 4. Leukoencephalopathy with calcifications, cysts, and retinal vascular 
abnormalities  
The patients of Study IV had a spectrum of manifestations – progressive extensive brain 
calcifications, cerebral cysts, leukoencephalopathy, retinal vascular abnormalities, and 
skeletal abnormalities – which overlapped with previous reports on ”Coats’ plus” 
syndrome or ”leukoencephalopathy, calcifications, and cysts” (Table 14), suggesting that 
all of these conditions are related. Recurrent episodes of intestinal bleeding, a feature not 
reported earlier, occurred in nearly half of the patients.  
 
Table  14. Previously reported patients with cerebral calcifications and leukoencephalopathy 
who are reminiscent of our patients. 
Feature Revesz 
et al. 
1992 
Labrune et al.  
1996 
Goutieres  
et al. 1999 
Sazgar et 
al. 2002 
Tolmie 1988 + 
Crow et al. 2004 
Nagae-
Poetscher et al. 
2004 
 
Gender m f m f f m m m f f f m m f f 
Age at onset 6m 11y 4y 3m 11m 3y 9m 1m 3y 1y 2.y 3y 2y 2y nm 
IUGR + nm nm nm + + + + + + + + nm - + 
Retinal angiomas or 
telangiectasias 
+ - - - + + + + +  + + + + - - 
Cerebral calcifications  + + + + + + + + + + + + + + + 
Cerebral cysts - + + + - - - - - - - - + + + 
Leukoencephalopathy +  + + + + + nm nm + + + + + + + 
Hair or nail 
abnormality 
+ - nm nm - - + + + + + + + nm nm 
Osteopenia/ skeletal 
changes 
nm - nm nm - - + + + + + - nm nm nm 
Pancytopenia +  - - - - - - +. - - - - - - - 
Hepatopathy - - nm nm - - - +  nm nm nm - - - - 
Cognitive decline + + dd + + - - - - - - - + + + 
 
nm, not mentioned; dd, developmental delay 
 
The findings in neuropathologic examinations suggest that the primary abnormality in this 
disorder is microangiopathy. Gradual obliteration of the cerebral small vessels could lead 
to dystrophic calcification via slow necrosis and then to formation of cysts. Strokes, 
common to other inherited  microangiopathies, e.g. CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy) (54, 124) and 
HERNS (hereditary endotheliopathy with retinopathy, encephalopathy and deafness) (58) 
did not occur. The extensive white matter abnormalities seem to represent secondary 
changes. The distribution of calcifications is reminiscent to that seen in mitochondrial 
disorders, but mitochondrial work-up of some of our patients and others (64, 83) was 
unremarkable.  
 
Retinal small vessels were abnormal in patients with early-onset disease. Both 
telangiectasias and angiomas were found. The ophthalmological abnormalities were not 
limited to changes seen in Coats’ disease, and thus the previous designation “Coats’ plus” 
might be misleading. A unifying feature in all five prospectively studied patients was 
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 avascular retina peripheral to angiomas and telangiactasias. A potential explanation for 
this is obliteration of retinal microvessels or, alternatively, incomplete vascularization of 
the retina during development.  
 
Components of the Wnt signaling pathway (LRP5, Frizzled-4, and NDP gene), involved in 
retinal vascular development (24) would be interesting candidates for a mutation search. 
Mutations in these genes are associated with familial exudative vitreoretinopathy (FEVR) 
and Norrie’s disease, vitreoretinal disorders in which abnormal vascularization of the 
peripheral retina is a key pathological feature (101, 120). FEVR, in particular, is 
characterized by retinal telangiectasias, exudation, and vitreoretinal folds resembling the 
findings seen in our patients. Mutations in the X-chromosomal NDP gene are responsible 
for Norrie’s disease, some cases of FEVR, and, apparently, some cases of sporadic Coats’ 
disease (13). LRP5 is also an important modifier of bone density (44), an interesting point 
regarding osteopenia in our patients. However, intracranial calcifications or cysts, so 
prominent in this disorders, have not been associated with mutations in these genes.  
 
These patients may represent an autosomally recessively inherited disorder. However, 
since the causative gene has not been identified, it is also possible that this phenotype 
turns out to be genetically heterogeneous. We have started molecular genetic studies of 
this disorder. 
5. Conclusions  
Leukoencephalopathies in childhood represent a heterogeneous group of disorders. When 
categorized based on MRI findings, the largest subgroups were patients with myelination 
abnormalities and patients with predominantly periventricular white matter abnormalities. 
 
Two recently described disorders were further delineated in this study: 
 
Leukoencephalopathy with brain stem and spinal cord involvement and elevated white 
matter lactate (LBSL). This disorder was clinically characterized by slowly progressive 
sensory ataxia, tremor, distal spasticity, and dorsal column dysfunction. Development of 
an axonal neuropathy was a new finding. 
 
Leukoencephalopathy with calcifications, cysts, and retinal vascular abnormalities. This 
study suggests that the previously reported rare cases of “leukoencephalopathy with 
calcifications and cysts” and “Coat’s plus” are manifestations of the same disorder. All 
autopsied patients had similar neuropathological findings showing calcifying obliterative 
microangiopathy. 
 
We have started genealogic and molecular genetic studies of these two disorders with the 
aim of identifying the genes underlying these clinically defined diseases. 
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 MRI findings in 18q- deletions were as follows: 
 
A typical MRI finding is a poor differentation of the cerebral gray and white matter on T2-
weighted images. This pattern is associated with deletions between markers D18S469 (at 
18q22.3) and D18S1141 (at 18q23). Haploinsufficiency of myelin basic protein is 
suggested to be responsible for the observed dysmyelination phenotype. 
 
The majority of patients with leukoencephalopathies remain without a diagnosis. Because 
these disorders are rare, delineation of new diseases requires long-term studies and multi-
institutional collaboration.  
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 APPENDIX 
Structure or 
finding no. 
 
Anatomic structure or finding 
1 Periventricular white matter involved? 
2 Lobar white matter involved? 
3 U-fibers involved? 
4 Predominantly involved white matter zone: periventricular? 
5 Predominantly involved white matter zone: lobar? 
6 Predominantly involved white matter zone: U-fibers? 
7 Global involvement of all white matter zones? 
8 White matter of the frontal lobe involved? 
9 White matter of the parietal lobe involved? 
10 White matter of the occipital lobe involved? 
11 White matter of the temporal lobe involved? 
12 Predominantly involved lobe: frontal? 
13 Predominantly involved lobe: parietal? 
14 Predominantly involved lobe: occipital? 
15 Predominantly involved lobe: temporal? 
16 Global involvement of all lobes? 
17 Cerebellar white matter involved? 
18 Posterior fossa white matter predominantly involved? 
19 Middle cerebellar peduncles involved? 
20 Pyramidal tracts involved? 
21 Central tegmental tracts involved? 
22 Medulla oblongata involved? 
23 Other brainstem tracts involved? 
24 Hilus of the dentate nucleus involved? 
25 Inner rim of the corpus callosum involved? 
26 Outer rim of the corpus callosum involved? 
27 Anterior part of the corpus callosum involved? 
28 Middle part of the corpus callosum involved? 
29 Posterior part of the corpus callosum involved? 
30 Anterior limb of the internal capsule involved? 
31 Posterior limb of the internal capsule involved? 
32 External and extreme capsules involved? 
33 Confluent abnormalities? 
34 Isolated multifocal abnormalities? 
35 Homogeneous abnormalities? 
36 Symmetrical abnormalities? 
37 Low signal intensity on intermediate-weighted images? 
38 Myelination delayed? 
39 Myelination arrested in an early stage? 
40 Myelination abnormal and irregular? 
41 Abnormality in myelination predominant pathologic finding? 
42 Cerebral cortex involved? 
43 Caudate nucleus involved? 
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 44 Putamen involved? 
45 Globus pallidus involved? 
46 Thalamus involved? 
47 Dentate nucleus involved? 
48 Cerebellar cortex involved? 
49 White matter volume loss? 
50 Ventricular enlargement? 
51 Enlarged subarachnoid spaces? 
52 Atrophy of cerebellar vermis? 
53 Atrophy of cerebellar hemispheres? 
54 Subcortical cysts? 
55 Intraparenchymal cysts? 
56 Frontal location cysts? 
57 Parietal location cysts? 
58 Occipital location cysts? 
59 Temporal location cysts? 
60 White matter swelling? 
61 Calcium depositions? 
62 Stripe-like pattern on sagittal images? 
63 Iron depositions? 
64 Other extra characteristics? 
65 Change over time: improvement? 
66 Change over time: stationary? 
67 Change over time: worsening? 
68 No second MRI obtained? 
Source (133). 
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